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DBC2 Literature Review 
The ability of cancer cells to proliferate and metastasize are commonly attributed to 
deletions and mutations of genes that regulate cellular growth cycles and programmed cell death 
(PCD a.k.a., apoptosis), or activation or suppression of their expression.  These genes commonly 
fall into two classes: proto-oncogenes that stimulate cell proliferation and tumor-suppressor genes 
that suppress cell growth. 
Deleted in Breast Cancer 2 (DBC2/RhoBTB2) is a tumor suppressor gene that has roles 
in suppressing cell proliferation and stimulating PCD. DBC2 was first identified through a 
Representational Difference Analysis (RDA) of human breast tumor biopsies (Hamaguchi et al.  
2002).  DBC2 was found to be deleted in 3.5% of the tumors assayed but now the expression of 
DBC2 has been shown to be lost in 60% of samples and has been linked to poor breast cancer 
prognosis (Hamaguchi et al., 2002; Mao et al., 2010). DBC2 was also identified in a loss of 
heterozygosity (LOH) screen from bladder cancer samples and is currently known to affect 
additional tumor and cells line such as lung, ovary, cervical, prostate, colon, rectum, kidney, 
stomach larynx and head and neck (Wilkins et al., 2004; Siripurapu et al., 2004; Berthold et al., 
2008; Mao et al., 2010.)    The deletion was mapped to chromosome 8p21.2 with six genes 




containing the PEST motif  in yellow, His rich region  in orange, NLS  in red, and the Ser 
rich element  in dark blue with  the putative RING domain  transparent brown.   Black 
spikes are the mutations from breast, lung cancer, bladder cancer maroon arrows, and 
gastric  cancer  blue  arrow.  Read  from  left  to  right,  V245A,  R275W,  Y284D,  D299N, 






2002).  The deletion focal point was noted to be within intron 7 of DBC2 extending into the 
3’ untranslated region (UTR) of a neighboring gene (Hamaguchi et al.  2002). The sequence loss at 
this location would be in excess of ~55% of the total gene coding region.   
The DBC2 domain structure was first thought to encode a Ras domain followed by tandem 
BTB (broad complex/bric-a-brac/poxvirus/zinc finger) domains (Hamaguchi et al.  2002). Upon 
further analysis the putative guanine nucleotide binding domain of DBC2 was found to be member of 
the atypical RhoGTPase class of G-protein domains. DBC2 is arranged from the amino-terminal (N-
terminal) end as a Rho domain followed by a PEST motif inside of a proline rich region, a tandem 
pair of broad-complex tramtrack, bric a brac/poxvirus zinc finger (BTB/POZ; referred to as BTB), a 
C-terminal domain containing a putative ring finger domain with a bipartite nuclear localization 
signal (NLS), ending with a serine rich region (Figure 1).  The first BTB domain has a bipartite 
arrangement with an approximate 106 amino acid (AA) spacer containing a poly-histidine rich region, 
a motif that is considered to be a signal for nuclear speckle localization (Salichs et al. 2009).   
The gene that encodes DBC2 shows evolutionarily specificity to mammals but include 
orthologs in Gallus gallus, Danio rerio, Dictyostelium discoideum, Drosophila melogaster and 
Anopheles gambiae (Hamaguchi et al, 2002; Ramos, S., et al., 2002; Siripurapu, V., et al., 2005; 
Vlahou, G. and F. Rivero, 2005).  In contrast, no apparent DBC2 othrologs have been found in plants, 
fungi, bacteria and archea and are also absence from the model organisms Caenorhabditis elegans, 
Xenopus laevis, and Saccharomyces cerevisiae (Hamaguchi et al, 2002; Ramos, S., et al., 2002; 
Siripurapu, V., et al., 2005; Vlahou, G. and F. Rivero, 2005). 
DBC2 has been shown to have numerous point mutations:  Y284D, R275W, D299N, E349D, 
D368A, and F647T as well as several silent mutations and intron related point mutations (Knowles et 
al. 2005, Hamaguchi et al. 2002, Wilkins et al. 2004).  In addition, two tumor specific mutations in 
the 5’ UTR of DBC2 have been identified.  One mutation possibly adds an additional transcription 
factor binding site, while the other eliminates two transcription factor binding sites including E2F1 
(Ohadi et al. 2007).  E2F1, which is known to regulate the expression of genes involved in cell cycle 
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progression and PCD, which has been shown to play a direct role in regulating DBC2 expression 
during the cell cycle (Freeman et al.  2007). Another study has indicated that the CpG islands within 
the promoter region of DBC2 are subject to aberrant methylation resulting in a significant decrease in 
DBC2 expression in cancerous tumors (Shi et al. 2008).  Many of these mutations listed above do not 
show a definite phenotype and/or have not been tested for effects on currently known DBC2 protein-
protein interactions.  
However, the D299N and Y284D mutations in DBC2 have been shown to have a reduced 
ability to inhibit proliferation compared to wild type in a DBC2 null back ground (Hamaguchi et al. 
2002, Wilkins et al. 2004).  The D299N was identified in the initial screen of somatic missense 
mutations in breast tumor specimens (Hamaguchi et al., 2002).  DBC2/D299N lacked anti-
proliferation activity in T-47D (Human ductal breast epithelial tumor cell line) compared to wt 
DBC2, and this mutation was rescued by the reintroduction of the wild type protein (Hamaguchi et 
al., 2002).. 
An additional investigation of other DBC2 mutants was conducted by Wilkins and co-
workers (2004), who examined the capacity of the Y284D, D299N and D368A to interact with Cullin 
3 (Cul3), the core component of Cullin-RING-Ligase (CRL) complexes, which functions as an 
ubiquitin E3 ligase. The binding of D299N and D368A to Cul3 was comparable to wt DBC2, whereas 
the Y284D failed to bind Cul3 (Wilkins et al., 2004).  The binding interface of DBC2 for Cul3 was 
localized to the first BTB domain of the structure (Wilkins et al., 2004).  Interestingly, the first BTB 
domain contains most of the currently identified DBC2 mutations (Knowles et al. 2005, Hamaguchi 
et al. 2002, Wilkins et al. 2004).  This study further identified the functional interaction between 
DBC2 and Cul3 in regards to Cul3 activation.  Cul3 is a protein that is regulated by neddylation.  
Neddylation is the covalent modification of an ubiquitin like modifier, nedd8, which causes a 
conformational change in the C-terminus of Cul3 that facilitates the transfer of ubiquitin onto the 
substrate (Choo et al, 2011).  Neddylation of Cul3 stimulates the binding of the COP9 signalosome 
(CSN) to Cul3, which then catalyzes Cul3’s deneddylation.  CSN mediated deneddylation  is essential 
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for Cul3 E3 ligase activity in vivo (Choo, et al 2001).  DBC2 was shown to interact with both non-
neddylated and neddylated Cul3, but not with any of the other cullin family members (Cul1,2,4a,5) 
(Wilkins et al. 2004).  This study also demonstrated that DBC2 turnover resulted from Cul3 mediated 
ubiquitination of DBC2 and its degradation via the 26S proteasome, as DBC2 levels were increase 
over time upon treatment of cells with the proteaosome inhibitor MG132 (Wilkins et al.  2004). 
Cul3 CRLs function in conjunction with a family of BTB-domain containing substrate 
receptors (Pintard et al., 2004).  Wilkins and co-workers proposed a model in which DBC2 functions 
as an addition substrate receptor for Cul3 regulating substrate degradation via the Ubiquitin/26S 
proteasome pathway.  Other BTB-containing substrate receptors have been shown to undergo auto-
ubiquitination in a manner similar to that observed for DBC2 (Choo et al., 2011). The mutations in 
DBC2 that inhibit its Cul3 binding would result in the stabilization of both DBC2 and its substrate 
target proteins (Wilkins et al. 2004).  It has recently been proposed that homo/heterodimerization 
between the Rho domain and BTB domain of the RhoBTB family members (see below) prevent 
DBC2 from forming a functional complex with Cul3, therefore stabilizing DBC2 and/or the other 
family members and preventing their degradation by CRL (Berthold et al. 2008).   The Cul3 mutant 
study along with proteasome inhibition via MG132 is indicative of CRL being the complex that 
targets DBC2 for degradation.  However, DBC2’s role in targeting associated proteins for degradation 
similar to Actinfilin (a BTB-Kelch protein family member) targeting subunits of the GluR6 kainate 
receptor for degradation through Cul3 is premature (Salinas et al., 2006).  Although both mutations 
have an effect that results in the loss of DBC2 anti-proliferation properties, D299N does not result in 
a loss of Cul3 binding as does the Y284D, indicating that DBC2 affects additional cellular pathways 
related to growth and differentiation (Wilkins et al. 2004).  
Functional roles for DBC2 were investigated through microarray analysis using endogenous 
DBC2 expressed in HeLa cells. This study linked DBC2 to processes influencing apoptosis 
(Siripurapu et al., 2005).  A recent study has linked the interaction of overexpressed DBC2 with Cul3 
to increased apoptosis, possibly through DBC2 playing a role in Anoikis, as it reduces the ability of 
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cells to form anchorage independent colonies (Mao et al. 2011). The microarray analysis also linked 
DBC2 to pathways involved in cytoskeleton dynamics (McKinnon et al., 2008).  DBC2’s 
involvement in aspects of cytoskeleton dynamics is supported by its involvement in the regulation of 
the chemokine CXCL14 expression (McKinnon et al., 2008).   CXCL14 is known to control cell 
migration and its expression is lost in a number of epithelial cancers (McKinnon et al. 2008).  
Another investigation linked DBC2 indirectly to cytoskeletal dynamics through the ability of 
ectopically expressed DBC2 to significantly increase levels of breast cancer metastatic suppressor 
(BRMS1), in conjunction with down-regulation of ezrin and Akt2 phosphorylation. Both BRSM1, 
and the Akt2/ezrin sytems affect the migration and invasion of cancer cells (Ling et al. 2010; Freeman 
et al. 2010). The additional pathways linked to DBC2 expression were membrane trafficking that was 
illustrated through DBC2-dependent microtubule-mediated transport of VSVG from the ER to the 
Golgi as well as the fluorescence localization of DBC2 to the microtubule network (Chang et al., 
2006). Cell cycle progression which been illustrated by DBC2 modulated down regulation of cyclin 
D1 (Yoshihara et al 2007) and the E2F1 modulation of DBC2 expression described earlier with 
limited DBC2 localization seen in the nucleus (Siripurpa et al., 2005; Freedman et al., 2008; 
Yoshihara et al., 2007; Chang et al., 2006). 
  The DBC2 domain structure has undergone a limited amount of analysis in initial 
investigations (Figure 1, 4a & 8). The DBC2 Rho domain was determined to be deficient in binding 
GTP due to the inability of wt DBC2 and a truncated DBC2 (1-160AA) to bind GTP (Chang et al. 
2004).  However, the possibility that DBC2’s GTP binding activity may be regulated through protein-
protein interaction or post-translation modifications, as occurs in other G-protein, must be considered.  
In the classical small G protein system these assistance factors are(i.e guanine nucleotide exchange 
factor (GEF), GTPase activating protein (GAP), guanine nucleotide dissociation inhibitor (GDI) 
along with the newly coined GDI displacement factor (GDF) (DerMardirossian et al., 2005), but for 
DBC2 one must consider that it might also be an otherwise unknown functional partner. For example, 
GTP binding to DBC2 may require GEF catalyzed dissociation of tightly bound GDP for GTP 
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binding (figure 4) (Aspenstrom et al., 2004; 2007).  The analysis was conducted via a Northwestern 
blot experiment with [-32P] GTP and recombinant DBC2 or truncated DBC2 (1-160AA) protein 
purified from Escherichia coli (Chang et al., 2006). It is plausible that wt DBC2 at 83 kDa had lost 
the ability to refold in an environment lacking molecular chaperones (e.g., DBC2 might require 
chaperones to prevent it from pursuing unproductive folding pathways, thus facilitating the folding 
process.)  The question of proper folding is even more relevant to the truncated DBC2 (1-160AA), as 
sequence alignments demonstrated that truncating DBC2 GTP-binding domain back to a Ras rather 
than as a Rho domain, deleted a section of its GTP binding pocket and additional structure that 
undoubtedly stabilizes the domain fold. 
A more comprehensive analysis of the amino acids must begin to determine the interactions 
of functional domains as single and/or complex entities.  This will begin to elucidate the processes, 
which are hindered in the absence of DBC2.  
Small G-proteins have highly conserved loop motifs required to bind and hydrolyze GTP (Paduch et 
al., 2001; Boureux et al., 2007).  The loop motifs and overall structure currently accepted are derived 
from the ancestral small G-protein, Ras (Paduch et al., 2001; Boureux et al., 2007; Salas-Vidal et al., 
2005).  However, the Rho GTPase falls under the Ras superfamily that is sub-divided into 6 families:  
Ras, Rho, Rab, Ran, Arf and Micro.  The Rho family is further subdivided into 8 subfamilies; 
Rho/Rif, Rac, RhoD, Cdc42, Rnd, RhoU/V, RhoH and RhoBTB (including DBC2) (Paduch et al., 
2001; Boureux et al., 2007; Salas-Vidal et al., 2005).   The Rho GTPase family has been shown to 
function in everything from cytoskeleton dynamics to programmed cell death (Knowles et al., 2005; 
Paduch et al., 2001; Salas-Vidal et al., 2005; Aspenstrom et al., 2004).  Nonetheless, this well 
conserved family includes the atypical Rho GTPase subfamilies Rnd, RhoU/V, RhoH and RhoBTB 
(Aspenstrom, P., A., 2007).  The sequence of the four subfamilies varies from that of the typical 
RhoGTPase (e.g., Ras) in conserved loop regions, catalytic residues (e.g. Ras conserved Gly 12 and 
Glu 61), absence of the characteristic isoprenyaltion CaaX motif, extended domain structure and/or 
regulation that is outside the control of the classical G-cycle (Figure 3).  Each of the subfamilies 
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meets one or more of the listed criteria (Boureux et al., 2007; Salas-Vidal et al., 2005; Aspenstrom et 
al., 2007).  Upon inspection of the DBC2 Rho domain, it was apparent that it had a domain structure 
containing amino acids that extended beyond the Ras domain structure. 
The atypical small GTPase RhoH has been shown to be constitutively active, even with 
residue specific substitutions that render Ras defective in binding of GTP (Aspenstrom P., A., 2007).  
RhoH functions to inhibit pathways activated by typical Rho GTPases and has been shown to 
positively regulate the signal dependent activation of the protein kinase, Zap70.  Thus, RhoH has 
been shown to maintain regulatory processes in both kinase and Rho dependent signaling 
(Aspenstrom P., A., 2007).    Another atypical small GTPase, RhoU (Wrch-1) has been shown to have 
a rapid GDP  GTP exchange, which produces a constitutively active form with no deleterious 
substitutions within the nucleotide bind region (Aspenstrom et al., 2004; Aspenstrom et al., 2007).  
The atypical subfamilies RhoH, RhoU/V, and Rnd have the ability to regulate the effectors (e.g. Pak1 
& WASP) of G protein modifiers and the cycling proteins (e.g. RhoGDI) required for typical and 
atypical Rho GTPase activity (Aspenstrom et al., 2007; Masuda-Robens et al., 2003).  The influence 
of guanine nucleotide binding on function of the RhoBTB subfamily is still to be investigated.  The 
appropriate sequence motifs to be classified as a Rho GTPase are not present within the provisional 
Rho domain of RhoBTB3, thus it is excluded from many analyses of this atypical subfamily; even 
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member to retain the isoprenylation motif at its C-terminus (Boureux et al., 2007; Salas-Vidal et al., 
2005; Aspenstrom et al., 2007).  The RhoBTB1 and RhoBTB2 (DBC2) sequences lack the conserved 
Q (Ras position Q61) that is necessary for catalysis of GTP hydrolysis in classical Rho GTPases 
(Chang et al., 2004; Paduch et al., 2001; Boureux et al., 2007; Salas-Vidal et al., 2005).   DBC2 also 
contains substitutions for classical consensus residues at GN in the P-loop, A  F in switch I, a 
(T/N)  C of loop G4 and A  V of loop G5 (Table 1) (Paduch et al., 2001; Boureux et al., 2007).  
The alterative residues located in the classically conserved binding/catalysis regions of the DBC2 Rho 
domain is suggestive of a function similar to the other atypical Rho GTPases, which remain in a 
constitutively GTP bound state (Berthold et al., 2008; Aspenstrom et al., 2007)..  Shown in more 
comprehensive sequence alignment is the reoccurrence of the consensus (T/N)  C substitutions that 
occurs in loop G4, which many Rho and Rnd proteins also contain (Boureux et al., 2007; Salas-Vidal 
et al., 2005; Aspenstrom et al., 2007).  The alteration of the classical consensus sequences of this 
atypical family could yield the regulatory functions necessary for their tissue specificity (Knowles et 
al., 2005; Ramos et al., 2002; Cho et al., 2007; Aspenstrom et al., 2007; Bement et al., 2006; 
DerMardirossian et al., 2005; Chen et al., 2006; St-Pierre et al., 2004).  The exclusive nature of this 
family is debatable with the identification of RhoBTB family members in many immortalized cell 
lines currently in laboratory use. 
The substitutions deviating from consensus for the DBC2 Rho domain were reported by 
Chang, F.K et al. (2006), to interrupt the ability of DBC2 to bind GTP. However, the Ras domain 
(e.g., only the first 160 AA) was used to evaluate the GTP binding capacity of the DBC2 (Chang, 
F.K., et al., 2006).   For the Rho structure this would result in a loss of loop G5, which has been 
determined to decrease affinity and hinder base discrimination (Paduch, M.F., et al., 2001).    The 
substitution of G  N in the P-loop (Ras positionGly12) puts the Asn in a curious position directly 
over the predicted binding pocket of the GTP -phosphate (Figure 2).  This could result in a novel 
form of self-regulation that engages other domains/motifs within the DBC2 architecture resulting in a 
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constitutively active and/or rapid cycling form, that were mentioned previously (Paduch, M.F., et al., 
2001).  There is a precedent for Asn to have the capacity to be involved in GTP hydrolysis without 
the presence of the catalytic Q61 (Ras reference).  For example, Rap1Gap utilizes an Asn rather than 
an Arg finger to catalyze the GTP hydrolysis.   Rap1 harbors a substitution of the catalytic conserved 
Q which is replaced by a Thr (Table 1) (Daumke et al., 2004; Rehmann et al., 2004). While the 
mechanism of GTP hydrolysis was not fully elucidated, site-directed mutagenesis of the Asn 
indicated that it was essential for Rapl GTP hydrolysis, with its motif being referred to as the Asn 
thumb (Daumke et al., 2004; Rehmann et al., 2004).  This proposes that hydrolysis of GTP can occur 
without the presence of the conserved Q61 that is retained by most classical small G proteins 
(Daumke et al., 2004; Rehmann et al., 2004).  Another example is the Ran GTPase shown to use a 
Tyr to activate the Glu for catalysis without donated residues from the RanGap (Seewald et al., 2002). 
The RanGAP instead acts in reorienting the native Ran residues into the correct orientation for 
efficient hydrolysis (Rehmann et al., 2004, Seewald et al., 2002).  Another alternative to classic GAP 
hydrolysis is the TBC domain that facilitates the hydrolysis of GTP bound Rab, through a dual finger 
mechanism donating both the Arg and Glu necessary for catalysis (Pan et al., 2006).  The classical 
Arg finger, as well as the other alternatives have a possibility to facilitate hydrolysis of GTP bound 
DBC2.  However, DBC2’s native residues are conceivably able to neutralize the charge of the bound 
GTP molecule (Paduch et al., 2001; Daumke et al., 2004; Rehmann et al., 2004; Seewald et al., 2002; 
Pan et al., 2006).    
The mechanisms for nucleotide binding must be re-investigated to elucidate how the DBC2 
Rho domain is regulated.  This includes any accessory proteins, post-translational modifications 
and/or, cofactors influencing the regulatory control for GTP binding.  
The tandem BTB domains that follow the Rho domain are the next functional domains 
(Figure 1).  The mutations known to affect DBC2 function have been predominately localized to the 
first BTB domain (figure 1).  Three of these mutations have been examined with moderate overall 







The general structure and functional properties attributed to the BTB protein families have been 
elucidated. BTB-domain containing proteins participate in many cellular and physiological functions, 
including: transcriptional regulation and chromatin remodeling; response to DNA damage; regulation 
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sequences of BTB domains showing very limited similarity (figure 5 & 6) (Kelly et al., 2006; Perez-
Torrado et al., 2006; Pintard et al., 2004; Stead et al., 2007; Stogios et al., 2005).  The sequence 
conservation is concentrated to residues in the hydrophobic core of the fold, predominately located in 
the 1, 3 and 4 of the core structure (figure 5 & 6) (Stogios et al., 2005).  The core is either N-
terminal, C-terminal or internally extended as the structures of the BTB subfamilies diverge (Figure 5 
& 6) (Stogios et al., 2005).   T1 (core) is composed of only the BTB core, while PLZF/BCL6 (Nt-
long) have a N-terminal 1/1 and 5 specific elements, with Skp1 (Ct-long) adding an 4 and C-
terminal 7/8;  ElonginC (short) lacks the A5 of the BTB core structure (figure 5 & 6) (Stogios et 
al., 2005).  An additional BTB fold has been illustrated in the Miz-1 (Nt-short) structure containing a 
N-terminal 1 in addition to the core fold without the β1 indicated for Nt-long form (Figure 5 & 6) 
(Stead et al., 2007). 
Taking these features into consideration the BTB structural elements residing distal and 
proximal to the essential core are variable outside of the current structural families.  However, the 
organization of the BTB domain confers its functional topology with most functioning as dimers, 
with many forming higher order structures such as tetramers and oligomers (figure 6) (Kelly et al., 
2006; Perez-Torrado et al., 2006; Pintard et al., 2004; Stead et al., 2007; Stogios et al., 2005). The 
oligomerization state of proteins depends on the structural elements within each individual BTB 
domain (Figure 6) Kelly et al., 2006; Perez-Torrado et al., 2006; Stead et al., 2007; Stogios et al., 
2005; van den Heuvel et al., 2004). The additional domains associated with a BTB domain results in 
their segregation into families.  The MATH (Meprin and TRAF Homolog)-BTB, BTBk (BACK-
Kelch), Rho-BTB, T1, Skp1, ElonginC and BTB-ZF (zinc finger) are the current conserved BTB 
protein families (Kelly et al., 2006; Perez-Torrado et al., 2006; Pintard et al., 2004; Stead et al., 2007; 
Stogios et al., 2005). The MATH-BTB is the most common BTB domain containing family (Kelly et 
al., 2006; Perez-Torrado et al., 2006; Pintard et al., 2004; Stead et al., 2007; Stogios et al., 2005).   
BTB domains are generally positioned at the N-terminus of the domain arrangement (Kelly et al., 
18 
 
2006; Perez-Torrado et al., 2006; Pintard et al., 2004; Stead et al., 2007; Stogios et al., 2005).  The 
BTB proteins have a plant-specific family, BTB-NHP3, which is thought to be an adaptor for a light 
activated signaling pathway (Stogios et al., 2005). Conversely, no BTB containing proteins have been 
identified in bacteria or Archaea (Stogios et al., 2005).  The arrangement of the BTB domains of 
DBC2 is an atypical arrangement with the BTB domains flanked at the N-terminus and C-terminus by 
an atypical Rho GTPase and a putative RING domain (figure 1).  The domain arrangement of DBC2 
comprised of two BTB domains postulates a potential lack of hetero or homo-quaternary forms for 
functionality.  Due to this, DBC2 has a deficiency in exclusive classification and adherence to 
consensus parameters.  This exemplifies the perception that DBC2 is an atypical protein, which 
potentially deviates from the functional activities known to the domains represented in the DBC2 
architecture.         
BTB protein families are quite diverse in structure and function, however; many share a 
common theme, substrate degradation via the ubiquitin/26s proteasome (figure 7). The pathway for 
protein ubiquitinylation/degradation involves three enzymes the E1 (Ubiquitin-activating enzyme), 
the E2 (Ub-conjugating enzyme) and the E3 (Ubiquitin -ligating enzyme a.k.a Ub-ligase) (Knowles et 
al., 2004; Siripurapu et al., 2005; Hori et al., 1999; McEvoy et al., 2007; Pintard et al., 2004; 
Vadlamudi et al., 2003; Welcker et al., 2003; Wimuttisuk et al., 2007).  The E1 activates the ubiquitin 
molecules with ATP followed by the covalently binding of ubiquitin to the E1 upon formation of a 
thiol-ester bound. The E1-bound ubiquitin is then transferred to the E2 through the formation of a 
thioester bond.  The E2 subsequently: 1) transfers the ubiquitin to a E3(HECT) target complex for 
subsequent HECT catalyzed transfer of ubiquitin to the substrate;  or 2) associates with an E3 (RING) 
complex, which ubiquitinates substrates by direct transfer of the ubiquitin from the E2 to the E3 
complex bound substrate (Pintard et al., 2004).  The C-terminal glycine of ubiquitin is used to form 
an isopeptide bond with the epsilon  
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amino group of Lys residues. The ubiquitin can then be extended and have been shown to be arranged 
into chains by attaching to lysine 6, 11, 27, 29, 33, 48 or 63 of other ubiquitin molecules before or 
after initial target protein attachment (Pintard et al., 2004). 
In this scheme, BTB proteins are shown to be an integral component of the Cul3 RING-H2-
type E3 ligase complex; CRL (Hamaguchi et al., 2002; Hori et al., 1999; McEvoy et al., 2007; Pintard 
et al., 2004; Vadlamudi et al., 2003; Welcker et al., 2003; Wimuttisuk et al., 2007; Singer et al., 
1999).  There are a number of the additional physiological responses associated to the BTB proteins, 
but protein degradation has been shown to be a common link to most of the BTB families. The 
Skp1/Cul1/Rbx/F-Box, SCF1, is potentially the most notable substrate degradation complex 
involving a BTB protein to date. But has been expanded to incorporate 
ElonginC/Cul2/ElonginD/SOCS, and Cul3/BTB/Rbx, CRL (Hori et al., 1999; McEvoy et al., 2007; 
Pintard et al., 2004; Vadlamudi et al., 2003; Welcker et al., 2003; Wimuttisuk et al., 2007; Singer et 












(Hamaguchi et al., 2002; Hori et al., 1999; McEvoy et al., 2007; Pintard et al., 2004; Vadlamudi et al., 
2003; Welcker et al., 2003; Wimuttisuk et al., 2007; Singer et al., 1999).  The DBC2 interaction 
gaining the most momentum is the DBC2 Cul3 complex, previously mentioned (Wilkins et al., 2006).  
The evidence that Cul3 binds DBC2 is adequate (Arnold et al., 2006; Kopp et al., 2006; Blom et al., 
2004; Kopp et al., 2006; Schwede et al., 2004; Bennett-Lovsey et al., 2008), but the conclusion that 
the second BTB domain’s lack of interaction with Cul3 is debatable (figure 8b).   The deletions made 
by Wilkins et al (2004), are consistent for the Rho and bipartite BTB domain. However, upon further 
analysis, the second BTB domain extends further upstream then the dissection point that was used 
(figure 8a) (Arnold et al., 2006; Kopp et al., 2006; Blom et al., 2004; Kopp et al., 2006; Schwede et 
al., 2004; Bennett-Lovsey et al., 2008).  As predictions for BTB domains were made using only the 
BTB core and not the N-terminal and C-terminal extensions specific to families (Stogios et al., 2005; 
Finn et al., 2006).  The interaction of the second BTB domain with Cul3 or additional cullins raises to 
possibility that DBC2 can form multiple degradation complexes as suggested by Perez-Torrado et al. 
2006.  Therefore, the overall regulation of signaling motifs, modifications and the tentative RING 
domain must be examined,  to gain insight into how specific domains function to: 1) regulate 
intramolecule interactions within DBC2 and interactions of DBC2 with other protein:  2)modulate 
DBC2’s localization, as its contains a nuclear localization sequence and likely undergoes 
nuclear/cytoplasmic shuttling;  and/or 3) determine the physiological significance DBC2 in normal 














A comprehensive analysis of DBC2 must consider the known DBC2 mutants that create 
impairments or enhancements, and is assessed here in order of increasing AA residues, as in Figure 1 
(Knowles et al. 2005, Hamaguchi et al. 2002, Wilkins et al. 2004); Chang et al., 2006).  The V245A 
mutation lies inside the Pro-rich region, but is a residue of the predicted PEST motif.   The online 
program PEST finder (Rechsteiner et al., 1996; Rogers et al., 1986) predicts that the V245A mutation 
(Stogios et al., 2005; Finn et al., 2006) increase the probability that the region functions as PEST 
motif, thus raising the possibility that the mutation shortens the half-life of the protein and decreases 
its availability.  The next mutation is the R275W, which has the potential of disrupting the conserved 
core fold R275 is predicted to be a solvent exposed residue of the 2 strand (unpublished data).   
Next, the Y284D mutation results in hindered binding of Cul3 leading to an extended DBC2 
lifetime (Wilkins et al., 2006).    However, the Y284D mutant would be incapable of targeting 
substrates to Cul3 for ubiquitination, and thus not be able to carry out its normal cellular function.  
The effect of the D299N mutation on DBC2 function was the first to be investigated in T47-
D cells by Hamaguchi et al (2002).  The mutation impeded and/or abolished the anti-proliferation 
effects of DBC2 compared to wild-type DBC2.  Upon further analysis, the mutation results in the loss 
of a clathrin box motif that is present on cargo adaptor proteins (Puntervoll et al., 2003; MotifScan).  
This alteration has the potential alter a regulatory motif that may function in vesicular trafficking 
reported by Chang et al (2006).  
The next mutant, D368A is predicted to result in the loss of a PDZ binding motif and a CKII 
(casein kinase 2) phosphorylation motif (Puntervoll et al., 2003; MotifScan).  The three mutants 
D299N, D368A and E349D (which shows no apparent motif alterations) are all located in the 
bipartite linker region that has a substantial probability to participate in the regulation of the first BTB 
domain and/or the overall DBC2 structure. The analysis of this region predicts a number of possible 
regulatory motifs, all having the capability to contribute to DBC2 regulation (Blom et al., 2004; 
Rechsteiner et al., 1996; Rogers et al., 1986; Puntervoll et al., 2003; MotifScan). 
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The G561S mutant is predicted to gain four motifs: a CK I (casein kinase 1), GSK3 
(Glycogen synthase kinase 3), SRC kinase and p38MAPK (p38 Mitogen-activated protein kinase 
phosphorylation site (Blom et al., 2004; Puntervoll et al., 2003; MotifScan)  This mutation is located 
in the turn leading from the 3 to the  core helix.  This substitution could affect the stability of the 
helix with the possibility of further disruption, if the residue is targeted for phosphorylation.   
The final known mutation is, F647T that is predicted to cause multiple possible alterations in 
function.  This mutation is positioned within the putative RING domain (unpublished data).  The 
putative RING domain is based on NBCI PSI-BLAST analysis related to NOT4, which consequently 
has been shown to have E3 ligase activity (Albert et al., 2002; Hanzawa et al., 2001).  This 
substitution located two residues C-terminal of the final Cys has the potential to disrupt the putative 
C2H2C2 motif.  The motif of this putative RING domain differs from NOT4, C4C4, and shows a 
relative similarity to the Hrt1, C3H2C2, which also has E3 ligase activity (Hanzawa et al., 2011; 
Mulder et al., 2007; Seol et al., 1999).  The predicted motifs created by this mutation have the 
potential to be destabilizing.  The mutation also creates a  p38MAPK, cdk5, (cyclin-dependent kinase 
5), CKII, PKC, (protein kinase C), and a ProD-kin1, (proline-directed kinase 1), phosphorylation 
motifs, and it also creates predicted FHA (Forkhead associating) and WW binding motifs that could 
generate multiple new regulatory signals (Blom et al., 2004; Puntervoll et al., 2003; MotifScan).   
  In conclusion, DBC2 is a newly identified tumor suppressor which has not be subjected to 
extensive analysis.  Its functional nature is still quite a mystery whereas the deciphering of the 
addition or loss of multiple motifs associate with inborn mutation along with protein-protein 
interactions, regulatory effects and localization of responses would be valuable in understanding the 
cellular pathways manipulated in response to DBC2. The identification of protein-protein interactions 
will aid in identifying initial functional and physiological responses to be investigated as they relate to 
DBC2.  Studies have been conducted identifying some physiological response to the presence or 
absence of DBC2, but have overlooked the functional regulation of DBC2 itself and the additional 
complexes that form to orchestrate these responses.  The curious domain structure of DBC2 requires 
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that a wide variety of regulatory mechanisms to be explored.    While, DBC2 has been identified as a 
tumor suppressor protein only a marginal amount of investigations have looked into the mechanism 
of action related to this function. The focus of the next chapter is on the characterization of DBC’s 






Functional Modulation of DBC2 by the Molecular Chaperone Hsp90 
Introduction 
It is estimated that approximately 290,000 new breast cancer cases will be diagnosed in 
the United States alone for 2011 (Breast cancer facts & figures 2011-2012).  They will be joining 
the estimated 2.6 million U. S. women who are already living with a history of breast cancer. 
Inherited mutations account for approximately 5-10% of breast cancer cases, with mutations in 
the BRAC1 and BRAC2 genes only accounting for less than a quarter of the familial cases 
(Breast cancer facts & figures 2011-2012).  An additional contributing gene, Deleted-in-Breast 
Cancer 2 (DBC2, a.k.a RhoBTB2) was identified in a  region of human chromosome 8p21, which 
was found to be homologously deleted in 3.5% of breast tumors (Hamaguchi et al., 2002; Mao et 
al., 2011).  In addition, expression of DBC2 was found to be silenced in 42% of breast cancer 
cells or tissues (Hamaguchi et al., 2002). Subsequent studies found that DBC2 expression was 
suppressed in approximately 60% of breast cancers (Mao et al., 2010), 50% of lung cancers 
(Wilkins et al., 2004), and 75% of bladder cancers (Shi et al., 2008).  Loss of DBC2 expression in 
bladder cancer was found to be associated with hypermethylation of  the gene’s promoter (Shi et 
al., 2008). Furthermore, missense mutations in the DBC2 gene were also identified (Hamaguchi 
et al., 2002, others).  Ectopic expression of wild-type DBC2, but not its mutants, in T-47D    
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breast cancer cells lacking DBC2 expression caused growth inhibition (Hamaguchi et al., 2002). 
While DBC2 is now firmly established to be an important tumor suppressor gene, little is 
known yet about its physiological function.  DBC2 is an atypical protein containing an amino-
terminal Rho domain followed by a proline-rich region, two tandem BTB domains and a 
conserved C-terminal domain with unknown function.  The BTB domain is so named as it was 
originally found in Drosophila transcription factors Bric à Brac, Tramtrack, and Broad Complex 
(Dhordain et al., 1995).  Besides transcription, BTB-containing proteins are involved in a wide 
range of biological processes, including the cell cycle and apoptosis (Berthold et al., 2008).   
 Microarray analysis indicated that DBC2 modulates the expression of gene networks that 
regulate cell growth via cell cycle control and apoptosis, and that are related to cytoskeletal and 
membrane trafficking (Siripurapu et al, 2005).  DBC2’s ability to suppress cell growth has been 
biochemically linked to its ability to down-regulate cyclin D1 expression (Yoshihara et al., 2007).  
In addition, the DBC2 gene has been shown to be a direct target of the E2F1 transcription factor, 
whose primary function is to modulate the expression of genes involved in cell cycle progression 
and apoptosis (Freeman et al., 2007). DBC2 expression has also been demonstrated to be required 
for the expression of the chemokine, CXCL14 (McKinnon et al., 2008).  While CXCL14 is 
expressed in most normal cells, its expression is very low or absent in many cancerous cells and 
tumors (Shellenberger et al., 2004), particularly those of epithelial cell origin. 
DBC2 ‘s association with the cytoskeleton and membrane trafficking is supported by the 
observation that DBC2 functions to facilitate microtubule-mediated transport of vesicular 
stomatitis virus glycoprotein (VSVG) from the endoplasmic reticulum (ER) to the Golgi 
apparatus (Chang et al., 2006).  Furthermore, inhibition of the migration and invasion abilities of  
MDA-MB-231 and MDA-MB-435 metastatic breast cancer cell lines upon ectopic 
overexpression of DBC2 was associated with increased expression of breast cancer metastasis 
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suppressor BRMS1 and decreased phosphorylation of ezrin, a key signaling molecule that 
regulates cell migration and invasion (Chang et al., 2006; Ling et al., 2010).  
The BTB-domain has structural homology with Skp1, a component of Cullin1 ubiquitin 
ligase complex and directs the docking of a subset of BTB-proteins to Cullin3 (Cul3).  The Cul3-
bound BTB-domain containing protein functions as a substrate specific adapter for Cul3 ubiquitin 
ligase complexes (Willems et al. 2004).  DBC2 has been demonstrated to interact directly with 
Cul3, and its levels appear to be auto-regulated through its interaction with the Cullin3 (Cul3) 
ubiquitin ligase complex (Freeman et. al., 2007; Wilkins et al., 2004.).  Tumor cell resistance to 
the overexpression of DBC2 is mediated via DBC2’s rapid destruction by the 26S proteasome 
(Collado et al. 2007). 
All the functions listed above have been proposed to occur without the binding of the 
Rho domain to GTP (Chang et al., 2006).  In this study, we show that DBC2 is a substrate (client) 
protein of the Hsp90 chaperone machine.  In addition, DBC2 was found to have retained the 
capacity to bind GTP like the atypical Rho GTPases Rnd and RhoH.  Furthermore, DBC2’s GTP 
binding ability was modulated by the Hsp90 chaperone machine with the inhibition of Hsp90 
ATPase cycle resulting in decreased or increased GTP binding, which correlated with inhibition 
of Hsp90’s entry or exit from its ATPase cycle, respectively.  Hsp90 is also demonstrated to 








Experimental Procedures  
Deletion Constructs:   
 
 All deletion mutants were constructed with the pcDNA3.1 vector.  All N-terminal deletion 
constructs containing truncations of the DBC2 ORF corresponding to specific structural regions, 
contain a pfu PCR derived Flag epitope tag at the 5’ end of the amplified insert. C-terminal 
deletions of specific structural regions were constructed using site-directed mutagenesis 
(Stratagene) to insert stop codons at desired locations using the full-length pcDNA3.1 Flag-DBC2 
as a template.    
In vitro coupled transcription/translation (TnT):   
 
Flag-tagged DBC2 and each deletion construct was synthesized by couple transcription/ 
translation (TnT) in nuclease-treated rabbit reticulocyte lysate (RRL) (Craig et al., 1992) 
containing [35S]-methionine for 30 min at 30°C in the presence or absence of 10 μg/mL 
geldanamycin, DMSO, 20 mM sodium molybdate (MoO4), or deionized water.  Where noted, 
Flag-DBC2 or deletion constructs were synthesized by TnT (T7 PCR TnT® Quick Master mix, 
Promega) supplemented with either [35S]-methionine or non-radioactive methionine for 90 min at 
30°C in the presence or absence of 10 μg/mL GA, DMSO, 20 mM sodium molybdate (MoO4), or 
deionized water For the TnT of Flag-DBC2 and its R99G, and V191I mutants, each construct was 
synthesized by PCR using the pfu polymerase (Aligent) with PCR primers containing a T7 
promoter and poly-A extensions at the 5’ and 3’ end, respetively according to manufactures 
protocol. The amplified DNA was then added to the TnT (Promega) supplemented with [35S]-
methionine for 90 min at 30°C in the presence or absence of 10 μg/mL GA, DMSO, 20 mM 
sodium molybdate (MoO4), or deionized water. In all cases, naïve RRL containing no template 
DNA was used as the control for the nonspecific binding. 
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Immunoprecipitation/GMP/GTP/Neutravidin/UBE pull-down assay:   
 
All samples were placed on ice, and then clarified by centrifugation for 7 min at (16,000 x g) 
prior to the immuno-adsorptions or pull downs. Samples were added to 12.5 μl IgG resin 
containing pre-conjugated anti-Flag-tag IgG (Sigma), 25 μl of GMP- or GTP-agarose, or 20 μl of 
Neutravidin- or UBE-linked agarose. Samples were incubated with resin for 1 hr at 4°C with 
mixing. Samples were then washed four times with either low salt buffer containing, 10 mM 
Pipes (pH 7.4), 100 mM NaCl, and 0.5% Tween 20 (P100T) or once with P100T, twice with high 
salt buffer containing 500 mM NaCl (P500T), followed by a wash with P100T.  Samples were 
boiled in SDS sample buffer, and analyzed by SDS-PAGE on an 8% gel, followed by 
electrotransfer to PVDF membrane (BioRad), followed by autoradiography or Western blotting 
for co-adsorbed proteins.  Samples quantified by scintillation counting were added to scintillation 
cocktail immediately following the final wash step and counted.  Samples for mass spectrometry 
were eluded from the Flag immunoresin by 100 mM ABC, 8 M urea and 4 mM EDTA.  Elution 
was carried out at 4°C for 30 min, and then supernatant was removed and stored at -80°C until 
LC-MS/MS analysis with an Obitrap XL mass spectrometer.  
Mammalian Whole Cell lysate preparation:  
  
MCF-7 and/or HeLa cells were grown to confluence in either 75 cm2 or 150 cm2 flasks in DMEM 
medium at 37 °C in 5% CO2.  Cells were detached using 0.25% trypsin for 10 min at 37°C.  Cells 
were then pelleted and washed once in fresh DMEM medium.  Following two additional washes 
in ice cold mammalian wash buffer, containing 35 mM Hepes pH 7.5, 140 mM NaCl and 11 mM 
glucose, the cells were mixed 1:2 in mammalian cell lysis buffer, containing 20 mM Hepes pH 
7.7, 140 mM KOAc, 1.0 mM Mg(OAc)2. The suspension was then placed into a Parr nitrogen 
disruption chamber (Parr Instrument Company.)  The Parr chamber was equilibrated with 
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nitrogen to 1200-1500 psi for 30 min at 4⁰C with stirring of the cell suspension during the 
equilibration.  After equilibration, the pressure was released and the lysate collected.  After 
collection, the lysate was centrifuged at (16,000 x g) for 12.5 min at 4°C.  Following 
centrifugation aliquots of lysate made, snap frozen in liquid N2 and stored at 80°C until use. 
Immunoprecipitation of DBC2 complexes reconstituted with HeLa or MCF-7 whole cell 
lysate for analysis by LC-MS/MS. 
 
At the completion of Flag-tagged DBC2 synthesis by TnT, samples (200 µl) were mixed with 50 
µl of either HeLa or MCF-7 whole cell lysate (WCL) prepared as described above, followed by 
incubation for 20 min at 30 oC..  The samples were then placed on ice, and clarified by 
centrifugation for 12.5 min at (16,000 x g) prior to the immuno-adsorptions. Samples were added 
to 30 μl anti-flag agarose (Sigma), incubated with resin for 1 hr at 4°C with rocking, and then 
washed five times with buffer containing, 10 mM Pipes (pH 7.4), 150 mM NaCl, (P150).  
Proteins were eluted from the anti-Flag agarose with 100 mM ABC, 8 M urea and 4 mM EDTA.  
Elution was carried out at 4°C for 30 min.  The supernatant was removed and stored at -80°C 
until LC-MS/MS analysis with an Obitrap XL mass spectrometer or the eluted samples were 
boiled in SDS sample buffer, and analyzed by 8% SDS-PAGE followed by electrotransfer to 
PVDF membrane (BioRad) for Western blotting for co-adsorbed proteins.  
The LC-MS/MS analysis of DBC2 associated proteins:  
The LC-MS/MS data was compiled by Scaffold for protein identification and then exported to 
Microsoft Excel for statistical analysis.  Duplicate biological samples were analyzed by LC-
MS/MS on an ORBITRAP XL mass spectrometer with three technical replicates using 
quantitative spectral counting.  Centroided ion masses were extracted using the extract_msn.exe 
utility from Bioworks 3.3.1 and were used for database searching with Mascot v2.2.04 (Matrix 
Science) and X! Tandem v2007.01.01.1 (www.thegpm.org).  Searches were conducted in the 
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current IPI or SWISS Prot human database using the following search parameters: parent ion 
mass tolerance 10 ppm; fragment ion tolerance 0.8 Da; and one missed tryptic cleavage. Gln-
>pyro-Glu of the N-terminus, oxidation of methionine, formyl of the N-terminus, acetyl of the N-
terminus and carbamidomethyl of cysteine were specified in Mascot and X! Tandem as variable 
modifications. Peptide and protein identifications were validated using Scaffold v2.2.00 
(Proteome Software) and the PeptideProphet algorithm. Probability thresholds were greater than 
99.0% probability for protein identifications, based upon at least 2 unique peptides identified with 
90.0% certainty.  Proteins that contained similar peptides and could not be differentiated based on 
MS/MS analysis alone were grouped to satisfy the principles of parsimony. Each ID contains at 
least four spectral counts on average per technical replicate, and was present in both of the 
biological samples with significant differences between the control and drug treated cells of 
p<0.5 (T-test). 
Antibodies used for Western blotting: 
Cul3- ab75851; DBC2 –N15 and C20 Delta Labs; G3BP1- sc-81940; DCP2 – ab28658; TIA-1 – 










































The Hsp90 chaperone machine has a plethora of client protein covering most aspects of 
cellular pathways and functions (current list; www.picard.ch/download/Hsp90interactors.pdf).  
Steroid hormone receptors (SHR) are a subset of the Hsp90 client proteins that have been 
extensively studied.  The SHR chaperone cycle which modulates the receptor’s hormone binding 
function, begins with the binding of Hsp70 and Hsp40.  Then, this complex binds Hop which 
facilitates the bridging of the SHR to Hsp90.  At this point in the cycle the SHR is unable to bind 
hormone.  It becomes competent to bind hormone after the binding of ATP, release of the Hsp70 
and Hop, and the recruitment of p23 and the immunophilin FKBP52.  Once in this complex the 
SHR is now ready to bind hormone and begin cellular signaling (Picard 2006).  This cycle is 
similar to the process that DBC2 goes through as it binds to the chaperones Hsp70, Hsp90 and the 
co-chaperone Hop (Figure 1, 2b, 5e).  Additional components of that are involved in the transition 
from early chaperone complexes to intermediate and late Hsp90 machine complexes are shown in 
Table 4, which includes Hsp40 (early) and p23 (late) chaperones complexes associated with 
DBC2 during its interaction cycle (Figure 8). 
This study further examined the binding of the chaperone machine in relationship to the 
domain structure of DBC2.  A multi-domain protein, such as DBC2, may contain multiple motifs 
that require Hsp90-assisted folding.  Cdc37, whose interaction with DBC2 initially identified it as 
a putative Hsp90 client, was also demonstrated to interact with additional motifs within the DBC2 
structure.  While Cdc37 interacted somewhat weakly with full length DBC2, it was observed to 
interact with DBC2 deletion mutants extending beyond the Rho domain until the bipartite linker 
region of the first BTB domain was deleted.  This area of the protein is rich in predicted 
phosphorylation motifs, among others post-translational modifications, with a strong possibility 
of Cdc37 participating in modulation of these modifications. 
The interactions of DBC2 with components of the Hsp90 chaperone machinery indicate 
that the Hsp90/Hsc70/HOP chaperone module strongly localized to the Rho domain of DBC2. 
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However, components of Hsp90 chaperone modules containing Cdc37 appear to interact with 
signaling motifs present distal to DBC2 Rho domain. 
The Hsp90’s modulation of DBC2’s GTP binding suggests that it is not regulated by 
mechanisms that modulate the classical G-protein GTPase cycle. The classical cycle includes 
guanine nucleotide exchange factors (GEF), facilitating the exchange of GDP for GTP.  GTPase- 
activating proteins (GAPs) that stimulate the catalysis of GTP to GDP.  GDP disassociation 
inhibitors (GDIs) that impede the replacement of GDP by GTP, and the newly coined GDI 
displacement factor (GDF) that stimulates the release of the GDI from the G-protein 
(DerMardirossian and Bokoch 2005). 
Atypical small GTPases have been demonstrated to function outside the framework of 
this classical GTPase cycle (Aspenstrom et al., 2007).  The families with characteristics that 
qualify them as atypical are Rnd, RhoBTB, Wrch-1/Chp, and RhoH (Aspenstrom, Ruusala et al. 
2007).  They all have in common altered GTP binding/hydrolysis capabilities.  For example, 
Wrch-1 (RhoU) has such a rapid nucleotide exchange rate in the absence of  any substitutions 
within the nucleotide binding consensus sequence, that it is considered to be constitutively bound 
to GTP (Aspenstrom, Ruusala et al. 2007).  Rnd, RhoH and RhoBTB proteins have substitutions 
in their conserved consensus GTP binding site.  However, the RhoH and Rnd proteins have been 
shown to remain in the GTP bound state, and to lack GTP hydrolysis activity (Aspenstrom, 
Ruusala et al. 2007).    Regulation of the Rnd G-protein is modulated through its degradation 
which terminates its functional activity (Chardin et al. 2006).  This is a mechanism proposed for 
the regulation of DBC2 function, with the Cul3 ubiquitin ligase system catalyzing the auto-
ubiquitination of DBC2 in the absence of bound substrates. The increase and decrease of GTP 
binding in response to inhibition of the Hsp90 ATPase cycle by molybdate and gelanamycin, 
respectively,(Figure 4c, d) suggests a functional modulation of GTP binding similar to that by 
which Hsp90 prepares the hormone binding domain of the SHR to accept hormone (Echeverria 
and Picard 2010) (Figure 8). 
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Exemplifying the GTP binding of DBC2 is the desthiobiotin activated GTP  cross-linking 
of biotin to DBC2.  The proposed crosslink is to Lys27 of the P-loop, which is also present in the 
other Rho mutants tested.  Each mutant retained the specificity for GTP binding, as well as 
having their GTP-binding activity modulated by the Hsp90 chaperone machine (figure 5b,d,e).    
The reduced GTP-binding of DBC2 in the presence of geldanamycin is reminiscent of the Hsp90-
bound glucocorticoid receptor (GR) in the presence of geldanamycin (Echeverria and Picard 
2010) in which the steroid hormone binding pocket remains inaccessible until Hsp90 progresses 
to its “late” complex conformation. 
The previously reported Cul3:DBC2 interaction was confirmed in this study with an 
expansion of the DBC2/CRL complex to include its interaction with the regulatory COP9 
signalosome.  The COP9 signalosome binding to Cul3 is required for the activation and 
regulation of its E3 ligase activity, and may function to stabilize DBC2 in the absence of Cul3 
target proteins, via COP9 deneddylation of Cul3 or direct COP9 mediated deubiquitination of 
DBC2 (Bosu et al., 2008). Regardless, COP9 signalosome preforms an obligatory  function 
closely associated with the ubiquitin proteasome pathway, which may be linked to the 
ubiquitinated protein mediator complex formed between COP9, VCP and USP15,  and thus it 
may play a potential role in the sorting of Cul3:DBC2 target proteins (Cayli et al., 2009). 
The identification of DBC2-associated E2 ligases (UBE2O, 22% coverage, 23 unique 
peptides, p=4.4E-16; and UBE2H, 36% coverage, 9 unique peptides, p=4.3E-7) and a HECT E3 
ligase (C12orf51, 17% coverage, 68 unique peptides, p=2.0E-35) by LC-MS/MS analysis of 
DBC2 pull downs, further supports a role for DBC2 as a substrate adapter for ubiquitin ligase 
complexes. In addition, the Cul4-associated substrate adapter DDB1, and the SKP1/Cul1- 
associated protein CACBP, which also presumably functions as a substrate adapter, were 
identified in pull downs of DBC2 from MCF7 lysates.  These findings suggest that there may be 
regulatory crosstalk between Cul3 E3 ligase complexes and the Cul4 and Cul1 E3 ligase 
complexes, in addition to the  hypothetical E3 ligase (C12orf51)(Angers et al., 2006, Wilkins et 
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al., 2006, Matsuawa et al., 2002).  This crosstalk may potentially involve E3 ligase modulated 
turnover of substrate adapters associated with other E3 ligase systems.  
The tolerance to the anti-proliferation effects of DBC2 by resistant HeLa cells can be 
attributed to sequestration of DBC2 into SGs, a structure that controls both stalled translational 
pre-initiation complexes that accumulate due to eIF2alpha phosphorylation that occurs in 
response to stress (Kedersha et al. 2005).  The lack of an association of DBC2 with the hallmark 
PB protein DCP2 indicates that DBC2 is solely present in SGs.  Since SGs, like aggresomes, 
contain aggregates of unfolded and ubiquitinated proteins that are to be target for degradation by 
the proteasome pathway, the previously reported rapid degradation of DBC2 may stem from 
DBC2’s involvement with SGs as a means of efficient sequestration and subsequent degradation 
(Brooks et al., 2010; Collado et al., 2007).   
The diversity of DBC2 interacting proteins identified in the sensitive MCF-7 cell line 
play roles in modulating many different areas of cellular function, the Cul3 E3 ligase and the 
proteasome pathway being previously discussed.  DBC2 is known to play a role in the regulation 
of cellular proliferation.  The identification of DBC2 interactions with other cell components will 
help to connect DBC2 to pathways that modulate cell proliferation, along with the currently 
recognized effects of DBC2 on CXCL14 and BRSM1 expression, in conjunction with Akt and 
ezrin phosphorylation (Ling et al., 2010; McKinnon et al., 2008).   
The association of DBC2 with additional cellular components involved in cytoskeletal 
dynamics and vesicular transport along microtubules and with motor proteins is consistent with 
its reported involvement in the transport of VSVGs from the ER to the Golgi (Chang et al., 2006.  
The identifications include association of DBC2 with the adaptor proteins AP-2A1, 2B1 and 3B1, 
connecting DBC2 to cargo protein selection during the formation of vesicles, which may explain 
DBC2’s link to components of the ER based chaperone machinery. 
The identification of the presence of ezrin in the DBC2 pull downs supports the 
interaction of DBC2 deduced by Ling (et al., 2010). DBC2’s interaction with the additional ERM 
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family member, moesin, further supports a role for the interaction of DBC2 with actin filament 
components at the plasma membrane (Aspernstrom et al., 2004).  DBC2/RhoBTB2 expression 
has been reported to have no effect on the organization of actin filaments. Instead 
DBC2/RhoBTB2 was found associated with vesicular structures suggesting a possible function in 
vesicular docking and fusion.  Such a role for DBC2 may explain the observation that DBC2’s is 
highly expressed during neurogenesis, suggesting that DBC2 may play a role in modulating 
synaptic vesicle formation and release, or vesicle trafficking that is required for synaptic pruning 
and/or growth (St. Pierre et al., 2004; Knowles et al., 2002).    
The possible involvement of DBC2 with chromatin remodeling is likely linked to its 
localization to paraspeckles through it His repeat motif (Salichs et al., 2009).  Paraspeckles are 
known to reside inside the nucleolus in the interchromatin space, and they have been suggested to 
play a role in transcriptional control: a function that is also connected to the COP9 signalosome 
(Fox et al. 2010; Chamovitz et al., 2009).  The proteins residing inside of paraspeckles have been 
shown to interact with RNA Pol II, and as such may be associated with active genes (Fox et al., 
2002).  Whether DBC2’s role is the regulation of transcription factors through Cul3 or a novel 
function controlling actively transcribing genes, but is noteworthy that several of the identified 
DBC2-associated nuclear proteins have known links to chromatin remodeling. 
The following model is proposed for Hsp90 in the modulation of DBC2 that is consistent 
with the effects of geldanamycin and molybdate on the interaction of Hsp90 chaperone machine 
components with DBC2, their effect on the binding of GTP to DBC2, aand DBC2’s interaction 
with Cul3 and the COP9 signalosome.  The Hsp90 chaperone machine is proposed to function as 
a molecular wedge that separates the DBC2 Rho domain from an intramolecular interaction with 
the BTB domain region, an interaction that suppresses its GTP binding activity.  Release of 
DBC2 from its auto-repressed conformation would free the BTB domains for binding to Cul3 and 
open the Rho domain to GTP binding (Figure 8).  This model is consistent with findings that the 
Rho domain of DBC2/RhoBTB2 interacts with its BTB region, which maintains it in an inactive 
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state, preventing its ubiquitination and degradation by the proteosome (Berthold et al., 2009).  
However, the modulation of the GTP binding and domain separation are not the only aspects of 
the coupling of the Hsp90 cycle to DBC2 function.  The Hsp90 chaperone machine also acts as a 
scaffold for the assembly of DBC2 complexes.  Geldanmycin-bound Hsp90 associates with 
DBC2 in its auto-inhibited conformation, which is lacking in GTP and Cul3 binding. Progression 
of the Hsp90 to the intermediate stage of its cycle releases DBC2 from its repressed conformation 
stimulating the binding of GTP and DBC2’s interaction with Cul3. The subsequent release of the 
Cul3-DBC2 complex from the Hsp90 chaperone machine allows components of the COP9 
signalosome to assemble into the Cul3/DBC2 E3 ligase complex.  It is not known whether 
neddylation of Cul3 occurs prior to its release from Hsp90, but the association of the core 
signalosome component CSN4 subunit with molybdate stabilized Hsp90/DBC2 complexes 
suggest it may occur while Cul3 is bound at the late stage in the Hsp90 cycle.  Thus, DBC2 must 
transit the entire Hsp90 ATP-driven reaction cycle for it to reach its full signaling potential.  
Whether Hsp90 facilitates DBC2’s assembly into additional non-Cul3 containing complexes, 
which function in other noted pathways, or whether these components are target of Cul3/DBC2 








Figure 8.  A representative model for the integration of the Hsp90 ATPase cycle with the 
modulation of DBC2 GTP binding/activation.  The DBC2 domains are: 1) Rho domain, 2) 
BTB1 domain, 3) BTB2 domain, and 4) putative RING domain.  The (x) is in reference to the 
Rho domain that is not competent to bind GTP.  “Cul3” and “CSN4” are used as example 
proteins whereas they can represent any know associating proteins.  “Early”,   “intermediate”, and 

























Wheat Germ Lysate a Cdc37 Null System 
Introduction 
  The Hsp90 chaperone machine interacts with many co-chaperone partners that are 
required for its interaction with client proteins and chaperoning function, providing it with the 
ability to serve a diverse set of clientele.  Cdc37 was first identified in 1980 as a protein involved 
in control of the cell cycle and was subsequently found to be what is coined the “kinase specific” 
co-chaperone of the Hsp90 chaperone machine (Reed et al. 1980; Schulz et al. 2001).  Cdc37 was 
designated  the kinase specific co-chaperone due to its interaction with Hsp90 protein complexes 
containing protein kinases clients, but its absence from Hsp90/ steroid hormone receptor 
complexes(Schulz et al. 2001).  A list of Cdc37 interacting proteins can be found at 
(www.picard.ch/download/cdc37interactors.pdf).  However, subsequently a specific interaction 
between Hsp90 and the androgen receptor was demonstrated, suggesting that Cdc37-associated 
clientele may extend beyond its interaction with protein kinases (Roe et al., 2001).   
Phosphorylation of serine 13 (Ser13) has been demonstrated to be necessary for the 
formation of Hsp90/Cdc37/kinase complexes (Shao et al., 2003).  Subsequently it has been 
proposed that Cdc37 undergoes a cyclic regulatory phosphorylation and dephosphorylation of 
Ser13 which is involved in the initial assembly and disassembly of the Hsp90:kinase:Cdc37 
complexes, respectively (Vaughan et al., 2008).  Cdc37 is composed of three functional domains,  
the N-terminal kinase binding domain, the middle Hsp90-interacting domain and a C-
terminal domain of unknown function (Shao et al. 2003).   
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Amino acids present in the first eight residues of Cdc37 are highly conserved and have 
been demonstrated to be critical for the interaction of Cdc37 with protein kinases (Shao et al. 
2003).  Additional residues, although not clustered in the primary sequence, are also highly 
conserved raising the question as to their contribution to Cdc37’s molecular function. Recently it 
has been proposed that Cdc37’s function is modulated by other post-translational modifications. 
However, Cdc37 has been shown to dimerize, such that the formation of a mutant/wild-type 
heterocomplex would have the possibility of masking the effects site-specific mutations designed 
to test the importance of these conserves amino acid residues in modulating Cdc37 function. 
Thus, the identification of a Cdc37 null system to assess the functional consequences of 
mutations to Cdc37 would be a substantial leap towards deciphering structure/ functional 
relationships that regulate Cdc37.  We have identified the Wheat germ lysate (WGL) system to be 
Cdc37 null, and demonstrate that it represents a useful model system to explore Cdc37 function 





Wheat germ In vitro coupled transcription/translation (TnT): 
Each protein construct was synthesized by coupled transcription/ translation (TnT) in WGL (SP6 
Quick TnT® Quick Master mix, Promega) supplemented with either [35S]-methionine for 2 H at 
25°C in the presence or absence of 10 μg/mL GA, DMSO, 20 mM sodium molybdate (MoO4), 
deionized water, recombinant p23, recombinant, or casein kinase II (CKII, Cell signaling).  Naïve 
WGL containing no template DNA was used as the control for nonspecific binding. 
Nickel (Ni) NTA pull-down assays:   
All samples were placed on ice, and then clarified by centrifugation for 12.5 min at (16,000 x g) 
prior to the pull-down. Samples were added to 15 μl Ni NTA resin, incubated with resin for 1 H 
at 4°C with mixing, and then washed four times with either low salt buffer containing, 10 mM 
Pipes (pH 7.4), 300 mM NaCl, 0.5% Tween 20, and 15mM Imidazole (P300T + 15mM 
imidazole).  Samples were then boiled in SDS sample buffer, and analyzed by SDS-PAGE on a 
10% gel, followed by electrotransfer to PVDF membrane (BioRad.) and analysis by 
autoradiography and Western blotting for co-adsorbed proteins.  The plant Hsp90 and p60 (Hop) 
antibodies were provided by Priti Krishna as was the CTR1 construct (AC101-CTR1).   
Tyrosine kinase assay: 
His-tagged Lck was generated by TnT in WGL in the presence or absence of Cdc37 
supplementation with or without the addition of geldanamycin, followed by pull-down with Ni 
NTA resin as described above. The activity of affinity isolated Lck kinase was determined 
incubation of resins with 0.5 µg/ml acid-denatured enolase and 1.0 mM ATP (normalized) in 
buffer containing 10 mM Pipes, pH 7.4, 150 mM NaCl and 20 mM MgCl2 at 22°C for 5 min.  
Boiling SDS sample buffer was added to the reaction. Then samples were separated by SDS-
PAGE and electrotransfered to PVDF followed by Western blotting for Tyr phosphorylation 
(anti-phosphotyrosine antibody, P-Tyo-100, Cell Signaling, #9411) to visualize enolase 
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phosphorylation.  Co-adsorption of Hsp90 and HOP were analyzed by Western blotting and 





Conserved Cdc37 residues 
The first 60 amino acids of Cdc37 are the most conserved across multiple species, 
suggesting that the residues play crucial roles in Cdc37’s structure and function (Figure 1).  These 
residues reside inside the kinase binding domain with the function of residues 2-8 of Cdc37 
having been tested by scanning alanine mutagenesis for their ability to bind Hsp90 and facilitate 
the maturation of protein kinases (Shao et al, 2003).  In addition, Ser13 has been demonstrated to 
be necessary for the formation of a ternary complex between Hsp90, Cdc37 and protein kinase.  
The mutagenesis of other conserved Cdc37 residues would further elucidate molecular 
mechanisms involved in kinase binding and maturation by the Hsp90/Cdc37 chaperone 
machinery.  As noted in the introduction, the propensity of Cdc37 to forms dimers makes 
interpretation of experiments in Cdc37-expressing cell system equivocal.  Thus, the identification 
of a system that is Cdc37 null would facilitate structure/ function relationships that govern 
Hsp90/Cdc37 modulated folding and activation of associated protein kinases.  
Cdc37 the missing component 
Analysis of the genomes of diverse species for genes encoding Hsp90 co-chaperones 
found no evidence for a gene encoding Cdc37 in plants (Johnson and Brown, 2009).  Therefore, 
we examined the well-characterized WGL system for its ability to reconstitute the binding of 
Hsp90 to newly synthesized protein kinase.  The A. thaliana protein kinase CTR1 was 
synthesized by coupled transcription/ translation in WGL.  Western blotting of pull downs of the 
newly synthesized His-tagged CTR1 indicated that no Hsp90 was bound to the protein kinase 
(Fig. 2, lane #). The WGL was then reconstituted with components that we have previously 
demonstrated to be required for complex formation or that are present in complexes formed 
between Hsp90 and protein kinase synthesized in rabbit reticulocyte lysate (RRL) (Cdc37, CKII, 
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and p23), to determine the component was the necessary to restore the presence of Hsp90 in 
complex with the kinase CTR1. The results presented in Figure 2 demonstrate that without the 
addition of Cdc37 the ternary Hsp90:CTR1:hCdc37 does not form.  In the absence of Cdc37, the 
amount of Hsp90 that was present in CTR1 pull down was equivalent to that present in the non-
specific binding control. Addition of CKII and/or p23 was not sufficient to restore the ternary 
complex.  Furthermore, addition of either p23 or CKII did not enhance the formation of this 
complex, consistent with homologues of these proteins being expressed in plants (Johnson & 
brown 2009) (Laxminarayana B, Krishna VM, Janaki N, Ramaiah KV, 2002). Similar to the RRL 
system, the addition of molybdate was not necessary to stabilize the formation of the Hsp90/ 
hCdc37CTR1 complex.  Thus, the only factor that affects the complex formation in WGL is 
Cdc37, as it was necessary and sufficient to restore the Hsp90/Cdc37/kinase ternary complex 
(Figure 2).   
The effect of geldanamycin on the reconstitution of the Hsp90/Cdc37/kinase complex.   
To determine whether the Hsp90/ Cdc37/ kinase ternary complex that was reconstituted in WGL 
had properties similar to those of the mammalian RRL system, we examine the effect of the 
Hsp90 inhibitor on the formation of the ternary complex.  In the RRL system geldanamycin 
prevents the formation of a stable complex between nascent kinases, Hsp90 and Cdc37 (ref). 
(figure 3).  The ternary complex reconstituted by the addition of hCdc37 responded to 
geldanamycin-inhibition in a manner similar to the complex formed in RRL.  The presence of 
geledanamycin disrupted the interaction of hCdc37 with Hsp90/CTFR1, preventing the formation 
of the complex (Figure 3, lanes 7-9). 
The influence of p23 on the autophosphorylation of the Hsp90 dependent kinase Lck in WGL 
To determine whether the addition of p23 would enhance the binding of Hsp90/Cdc37 to 
the human Hsp90-dependent kinase Lck in WGL and affect its auto-phosphorylation, Lck was 
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synthesized in the presence or absence of p23 in the presence of Cdc37.  No significant 
enhancement of Hsp90/Cdc37 binding or auto-phosphorylation of Lck was observed upon 
addition of human p23 to WGL (Figure 4).  Thus, wheat germ ortholog of p23 is functional and 
present in adequate supply, further supporting the conclusion that the only limiting factor in 
reconstitution of Hsp90/kinase complexes in WGL is Cdc37 (Figure 4).  
Hsp90-dependent activation of Lck in WGL 
To test the utility of the WGL system for studying the Cdc37-dependent stabilization of 
the interaction of Hsp90 with protein kinase, the Hsp90-dependent client kinase Lck was generate 
in the presence or absence of hCDC37 by TnT in WGL with and without the addition of 
geldanamycin.  The properties of Lck generated in WGL was similar to the properties Lck 
exhibits when synthesized in RRL (ref).  The supplementation with Cdc37 was necessary for the 
for the reconstitution of stable Hsp90 binding to Lck (Fig.5).  However, in the absence of 
hCdc37, Lck kinase was active in phosphorylating the model substrate acid-denatured enolase in 
vitro, and geldanamycin had minimal inhibitory effect on Lck’s kinase activity (Fig. 5). 
Supplementation of WGL with Cdc37, stabilized the binding of Hsp90 to Lck, and stimulated 
Lck’s kinase activity as measured by phosphorylation of enalose. The addition of geldanamycin 
blocked Hsp90/Cdc37/Lck complex formation and the ability of hCdc37 supplementation to 
stimulate Lck’s kinase (Fig. 5). Western blot analysis of the Lck pull downs indicated that the 
Hsp90 co-chaperone Hop was specifically bound the Lck and that interaction was not disrupted 
by addition of geladanmycin or supplementation with hCdc37 (Fig. 5).  In non-plant systems, the 






Figure 1. Sequence alignment of the first 60 amino acids of Cdc37 from various 
organisms.  H.s (Homo sapiens- sp_Q16543), M.m (Mus Musculus- Q61081), B.t (Bos 
Taurus- sp_Q5EAC6), R.t (Rattus norvegicus- sp_Q63692), S.s (Sus scrofa- 
tr_Q684M6), G.g (Gallus gallus- sp_O57476), C.e (Caenorhabditis elegans- sp_O02108), 
C.b (Caenorhabditis briggsae- tr_A8X3Q4), B.m (Bombyx mori- tr_Q5CCL4), X.t 
(Xenopus tropicalis- tr_Q28CE8), D.r (Danio rerio- tr_Q7ZV56), T.f (Tetraodon 
fluviatilis- sp_Q9DGQ7),S.sa (Salmo salar- tr_B5X4J1), L.s (Lepeophtheirus salmonis- 
tr_C1BSQ2), S.j (Schistosoma japonicum- tr_C7TQQ3), D.m (Drosophila melanogaster- 
tr_Q86NM8), A.f (Aspergillus fumigates- tr_Q4WPP7), S.p (Schizosaccharomyces 
pombe- sp_O94740), S.c (Saccharomyces cerevisiae- sp_P06101), C.g (Candida 
glabrata- tr_Q6FVL7), C.d (Candida dubliniensis- tr_B9WIX2), C.a (Candida albicans- 
sp_Q8X1E6). The large box encases residues 2-8 of the Homo sapiens Cdc37 protein 
along with the aligned residues of the various species, these residues were analyzed by 
alaine scanning mutatgenesis.  The small box indicates the invariant serine residue, which 
is critical to the function of Cdc37 in the Hsp90 chaperone machinery, also were 
analyzed with an alanine (A) and glutamic acid (E) substitution via site-directed 
mutagenesis.  Representative labeling, (*)- denotes an invariant residue, (:)- denotes a 
























































Figure 3.   Ternary complex response to GA  inhibition.    .   35S‐met  labeled His‐tagged CTR1 and 
hCdc37 were  synthesized  in WGL  in  the presence or absence of DMSO or GA and pull‐down 
























Figure 4.  35S-met labeled His-tagged hLck and no tag hCdc37 were synthesized in WGL in the 
presence or absence recombinant  p23 followed by a pull-down using Nickel NTA resin and 
washed 4 times using P300T with 15mM Imidazole.  hLck and cdc37 (middle panel) were 
analyzed through  autoradiogram with western blotting plant Hsp90 (top panel).  Lane 1 is the NS 

































Figure 5.  The response to GA inhibition along with activation with hLck in WGL. .  35S-met 
labeled His-tagged hLck and hCdc37 were synthesized in WGL in the presence or absence of 
DMSO or GA and pull-down using Nickel resin was followed by washing 4 times using P300T 
with 15mM Imidazole.  hLck and cdc37 (middle panel) were analyzed through  autoradiogram 
with western blotting plant Hsp90 and p60 (Hop) (top panel). Testing the activity of the hLck 
synthesized in WGL in the presence and/or absence of GA and cdc37 and western blotted Tyr 
phosphorylation of enolase (Y100) (bottom panel). Lanes (1, 5) represent the NS translation and 
binding control, lanes (2-4) are only hLck without the addition of translated hCdc37 and lanes (6-
8) contain hLck with the addition of translated hCdc37.  Lanes (4, 8) all contain the Hsp90 







The kinase binding domain of cdc37, containing the most highly conserved sequence, has 
the ability to supplement and maintain yeast viability when Hsp90 function is deficient or in the 
absence of Sti1 (the yeast Hop homolog) (Lee et al., 2002).  The functionality is attributed to the 
inherent chaperone function associated with Cdc37 even in the absence of its association with 
Hsp90 (Lee et al., 2002).  Cdc37’s Hsp90 binding domain interacts with Hsp90’s N-terminal 
domain and blocks its ability to bind and hydrolyze ATP during the client loading phase of the 
Hsp90 ATPase cycle (Roe et al, 2004).  Structure/function relationships that govern Cdc37’s 
binding to Hsp90 and kinase and its ability to support kinase maturation are of great interest 
because of the oncogenic nature of many of its substrates, along with the oncogenic properties of 
the over-expression of Cdc37 itself (Pearl et al., 2005).  The presence of Cdc37 is essential for 
viability in yeast, Drosophila and Caenorhabditis elegans (MacLean et al., 2003), making the 
identification of a Cdc37 null system, such as wheat germ lysate (WGL), a significant technical 
stride.  Structure/ function relationships governing Cdc37’s activities can now be studied without 
interference of a background expression of wild-type Cdc37, circumventing the problem that 
might arise due to Cdc37 dimerization and the formation of wild-type/ mutant Cdc37 
heterocomplexes that may potentially mask the effect of the mutation  (Roiniotis et al., 2005).  
Cdc37 was identified as the co-chaperone that was necessary and sufficient to 
reconstitute the Hsp90: kinase complexes in WGL, consistent with the observation that Cdc37 is 
essential in promoting the formation of Hsp90/kinase complexes in other eukaryotic cell systems 
(Smith et al., 2008).   The reconstituted WGL/Cdc37 was found to have properties similar to 
those of RRL, with the Hsp90 inhibitor geldanamycin disrupting the binding of Hsp90 and Cdc37 
to the Arabidopsis Ser/Thr kinase CTR1 and to the human Lck tyrosine kinase. 
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  Of interest, however, is the observation that the Lck kinase expressed in WGL has 
significant kinase activity in the absence of supplementation of the lysate with Cdc37. While 
Cdc37 supplementation stabilized the binding of Hsp90 and Cc37 to Lck and stimulated Lck’s 
tyrosine kinase activity, Lck’s maturation was not entirely contingent on the presence of Cdc37. 
The stimulation of Lck’s kinase activity was due to the presence of Cdc37, as this stimulation was 
lost upon addition geldanmycin. Curiously, a stable association of HOP with Lck was observed 
both in the presence and absence of geldanamycin, and the interaction was not inhibited in the 
presence of Cdc37. These observations suggest that HOP may function in kinase maturation in 
the plant system in lieu of Cdc37. While an interaction of HOP with protein kinases have not 
been observed in mammalian cell systems, Sti1 (yeast HOP) has been demonstrated to play a role 
in stabilizing Hsp90/kinase complexes in yeast (Lee et al 2004).  Thus, in addition to its utility in 
studying structure function relationships that regulate Cdc37, the WGL system may also facilitate 
studies examining the role of Sti1/HOP in kinase maturation which may occur in other eukaryotic 
cell systems, particularly the Plasmodium and Trypanasomal pathogens which have a gene 
























The Direct Binding of Novel Small Molecule inhibitors of Hsp90 
Introduction 
Surface Plasmon Resonance, (SPR,) is an optical technology able to detect direct 
interactions of biomolecules as the mass changes on the sensor surface.  SPR has gained 
popularity in the biomedical industry mainly due to the development and optimization of both the 
instruments and methods, in the field over the past two decades (Thillaivinayagalingam et al. 
2010.)  The tremendous strides into the identification and characterization of direct interactions of 
biomolecules with ligands, whether the ligand is a protein or a small molecule has made this 
technology more attractive to the academic sector as well as industry.  The SPR technology along 
with a nano-scale flow system reaches further towards replacing the high reagent consuming 
coupled enzymatic reactions previously used to determine the kinetics of a reaction.  This label-
free real time method allows for the binding and dissociation kinetics to be calculated with more 
certainty, and thus binding affinities have more accuracy then those previously gathered.  All 
information reviewed in Shiau et al., 2008; Rich et al., 2008; Thillaivinayagalingam et al., 2010; 
Merwe; Bokatzian-johnson, 2008.       
SPR detection is based on ability to generate surface plasmons at the interface of materials that 
differ in refractive index.  The generation of surface plasmons begins with a beam of plane 
polarized light directed at back of the sensor surface which results in an evanescent wave 
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exciting the electrons in the gold coated sensor surface that is in direct contact with the 
assay medium on the other side of the glass surface.  This in turn causes a change in the strength 
of the reflected light. When the refractive index at the surface of the sensor is changed, the angle 
of reflected light is altered which is known as a resonance signal. This resonance signal is directly 
proportional to the change in mass at the sensor surface caused by the binding of the analyte to 
the immobilized ligand and is recorded as response units (RU) which corresponds to the shift of 
the measured angle (Figure 1.) 
 
 
Figure 1:  Theoretical sensorgram depicting a SPR data collection run.  Inserts show the 
composition and arrangement of ligand and analyte at each phase of the sensorgram.  Black flags 




SPR in terms of a bimolecular application begins with surface chemistry that is applied to 
the gold coating on the sensor surface.  This begins with the application of a layer of molecules to 
ensure proper spacing between the biomolecules and the gold surface, but also carries a 
carboxylic acid group for subsequent reactions.  There are many different variations for the next 
layer, but for this example we with explore a covalent immobilization (amine coupling) and the 
capture approach (NeutrAvidin:biotin.)  The first is considered to be the most popular, and 
involves immobilization of a protein through free primary amines. First the carboxylic acid 
groups on the surface of the sensor are activated to which the protein of interest is then covalently 
linked. After the quenching of any free reactive group generated that remain on the sensor’s 
surface, the sensor is ready for data acquisition.  The second method begins with covalent amine 
coupling of Neutravidin to the sensor surface as mentioned above, but the protein (ligand) of 
interest is not directly immobilized to the sensor surface.  The protein is first derivatized, in this 
case with the addition of a biotin for capture by the surface immobilized Neutravidin.   
The next steps are both consistent for each of the methods of protein capture.  The 
analyte at multiple concentrations is injected over the protein (ligand) bound sensor surface with 
the RUs recorded in real time being the result of ligand-analyte interaction.  This measurement 
allows for the accurate kinetic information to be derived in real time for the reasons mentioned 
above.   
There are many advantages to this method:  it is label free; it continuously monitors 
kinetic events (the binding and dissociation of the analyte from the ligand); and it allows for the 
analysis of a large number of samples.  As for all methods there are some disadvantages as well 
that could pose a problem: sufficient amounts ligand must be immobilized to reproducibly detect 
a signal; the ligand/ chip linkage in the analyte buffer must be robust; and the stability of the 
immobilized protein used for the assay. There are methods to ensure and/or test for each of these 
disadvantages during the assay development for each particular experimental setting.  All of these 
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factors must to be taken into consideration before it can be ascertained whether SPR can be used 
to address a given experimental question.  With all the powerful features that SPR has it is surely 
to become a common technology utilized in the years to come.  All information reviewed in 
Shiau et al., 2008; Rich et al., 2008; Thillaivinayagalingam et al., 2010; Merwe; Bokatzian-



















Surface Plasmon Resonance (SPR): 
SPR experiments were performed on the ICX, Nomadics SensiQ instrument using 
Hamilton syringes for injection of assayed materials.  All measurements were done in triplicate 
and SPR binding curves were analyzed using QDAT software (ICX Nomadics) to calculate the 
ka, kd,and KD data.     
Protein binding buffer consisted of 10 mM Hepes buffer (pH 7.4) containing 150 mM 
NaCl. Sample and assay running buffer contained 10 mM PIPES (pH 7.4), 300 mM NaCl, and 
2% DMSO or 5% DMSO.  The N-terminal Hsp90 construct (Hsp90NT) corresponded to amino 
acids 1-241 with a C-terminal-GELRSGC tail due to a pET151 TOPO 3’ vector extension. The 
C-terminal Hsp90 construct (Hsp90CT) corresponded to amino acids 531-732     
Protein preparation: 
Insect Sf9 cells overexpressing human Hsp90β were cultured and harvested by the 
Baculovirus/Monoclonal Antibody Core Facility at Baylor College of Medicine and purified 
according to Grenert et al. (1997) and Owen et al. (2002.)  However, the initial DEAE-cellulose 
chromatography step was omitted.  
Bacterial expressed His-tagged full length Hsp90 (Hsp90FL), Hsp90NT and Hsp90CT 
were grown in DE3 star E.coli and purified using a NiNTA affinity column, followed by cleavage 
of the N-terminal His-tag by TEV protease (Invitrogen) after purification. Following epitope tag 
cleavage the proteins were further purified by size-exclusion on a Superdex 200 column. 
Bacterial or Sf9 expressed purified recombinant proteins were passed through a desalting 
column (BioEdge) into a buffer containing10 mM HEPES (pH 7.4) and 150 mM NaCl to prepare 
the proteins for immobilization to a COOH sensor surface.  For immobilization on Neutavidin 
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sensor chips, proteins were biotinylated by reaction with EZ-Link® Maleimide-PEG2-Biotin 
(Thermo Scientific) according to manufacturer’s protocol, followed by passage through a 
desalting column (BioEdge) into buffer containing 10 mM HEPES (pH 7.4), and 150 mM NaCl 
to prepare them for binding to Neutavidin.   
Protein immobilization: 
Sensor normalizations were carried out using protocols developed by Dr. Shawn Daley and Ms. 
Kristen Szabla (OSU Biochemistry and Molecular Biology department) in conjunction with ICX, 
Nomadics.   This method was developed through personal communication and interaction with 
Dr. Shawn Daley.     
Proteins were immobilized on COOH sensor chip surfaces as follows:  The surface of a 
SSO1 COOH sensor chip was normalized and activated by treatment with Nˊ-3- 
dimethylaminopropyl-Nˊ-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide for 
preferential cross-linking of full-length Hsp90s N-terminus to the surface. For immobilization of 
Hsp90, 250 μL of Hsp90 (6.2 mg/mL) in 10 mM Hepes buffer (pH 7.4) containing 150 mM NaCl 
was discrete-injected over the sensor’s experimental surface at a flow rate of 5-10 μL/min, 
resulting in 2000 response units of protein captured. Then, 1 M ethanolamine (pH 8) was used to 
quench the remaining activated groups, and the surface subsequently washed with assay running 
buffer. 
The surface of a SSO3 BioCap SPR sensor chip was mounted in a SensiQ SPR 
instrument (ICX Nomadics), and either the biotinylated Hsp90NT (7.0 mg/mL) or Hsp90CT (6.8 
mg/mL) was discrete-injected over the experimental channel at a flow rate of 5-10 μL/min, 
resulting in the capture of Hsp90NT and Hsp90CT at 1250-1400 response units of protein on the 
sensor experimental surface, respectively. The sensors were subsequently washed with assay 
buffer prior to experimental analysis. 
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The various compounds were diluted in assay running buffer containing 10 mM PIPES (pH 7.4), 
300 mM NaCl, and 2% DMSO and injected over the surface of each protein bound sensor at a 
flow rate of 15 μL/min at 25°C at the indicated concentrations.  The dilutions of all compounds 
were specifically matched to the assay running buffer to minimize index shifts induced by the 
DMSO.  Curves were double referenced to subtract contributions of the buffer containing 2% 
DMSO to the response units. 
Competitor solutions 
Geldanamycin competition studies were conducted using a constant 20 μM concentration of 
geldanamycin in the sample and running buffer.  The concentrations of Gambogic acid were 













Results and Discussion 
KU174 
Interaction of KU174 with Hsp90β was analyzed by surface plasmon resonance (SPR) 
spectroscopy. KU174 is a proprietary compound designed by the laboratory of Dr. Brian Blagg 
from the University of Kansas. Various concentrations of KU174 were injected over Hsp90FL 
bound to the sensor surface (Fig. 2).  The response units generated during the injections 
illustrated that KU174 directly interacted with Hsp90 (Fig.2A).  The kinetics of KU174 binding 
to and dissociating from Hsp90 were reliably fitted to a pseudo-first order model for a 1:1 
interaction with the ka and kd calculated to be 1.04x10
3 (M-1.sec-1) and 0.098 (sec-1), respectively. 
The Kd estimated from the fitting of the binding curve (Fig. 1B: 78 µM  7 s.e.) was in close 
agreement with the Kd estimated from the ratio of the dissociation and association constants (94 
µM  4 s.e.).  In comparison, the ka and kd for the binding of novobiocin to Hsp90β were 211 (M-
1.sec-1) and 0.23 (sec-1) (calculated Kd of 1.1 mM  0.4 s.e), with a Kd calculated from the binding 
curve of 0.86 mM  0.02 s.e.).  Thus, the SPR analysis of the interaction of KU174 with Hsp90β 
indicated the compound bound directly to the purified recombinant protein with a reasonably high 














Figure 2. Anaylsis of the binding of KU174 to Hsp90β by SPR.  KU174 was injected over 
Hsp90β immobilized to the surface of a SPR sensor chip at concentrations of 0.25, 0.5, 1.0, 10, 
50, 100, and 200 µM as described under “Materials and Methods”. (A.) Sensorgrams of KU174 





Gambogic Acid:    
Gambogic acid (GBA-appendix A) was identified through a high throughput screen of a 
natural product library for inhibitors of Hsp90-dependent refolding of thermally denatured firefly 
luciferase.  In vitro studies indicated that GBA functions similarly to known Hsp90 inhibitors (e.g 
GA-appendix A, Davenport et al, 2011), inhibiting the Hsp90-dependent maturation of the heme-
regulated eIF2 alpha kinase (HRI) and blocking the interaction of HRI with Hsp90 and its co-
chaperone Cdc37. SPR was carried out to determine if GBA interacted directly with Hsp90 and 
whether GBA binding was localized to Hsp90’s N- or C-terminal domain.  
Hsp90FL showed a strong response to the presence of GBA (Figure 3) indicating that 
GBA interacted directly with Hsp90. To determine which domain the GBA binding site, 
Hsp90NT and Hsp90CT were analyzed for their ability to interact with GBA. Hsp90NT was 
found to bind to GBA with an affinity similar to Hsp90FL, with no measurable response being 
detect with GBA was inject over the immobilized HSP90CT sensor surface.      
To determine whether GBA bound to the same site in Hsp90NT as GA, GBA was 
injected over the sensor surface in the presence of a constant 20 µM concentration of GA in both 
the assay and sample buffer.  GA did not have any significant effect on the binding of GBA to 
Hsp90NT, with the calculated GBA binding affinity being comparable to that of GBA binding in 
the absence of a nucleotide binding cleft competitor (Table 1).  Thus, GBA appears to bind to a 
novel Hsp90 N-terminal domain binding site, as GA, a known nucleotide binding cleft inhibitor, 















Figure 3.  SPR analysis of the interaction of gambogic acid (1) with (A) full length Hsp90 and 
(B) the N-terminal domain of Hsp90.  A. Injection of 1.0, 10, 25 and 50 M 1 over a SPR chip 
containing bound full length Hsp90.  B. Injection of 0.5, 5, 15 and 25 M 1 over a SPR chip 













Table 1. Constants for the Binding of Gambogic Acid (1) to Hsp90 
protein  ka (M
-1 S-1) kd (S
-1) 
KD 
(μM)   
full length Hsp90  1.16(8)e3 0.0113(4) 9.8(2)   
Hsp90NT 1.47(6)e3 0.01122(7) 7.6(3)   
Hsp90NT (+20µM 
GA) 1.62(8)e3 0.0114(7) 7.0(4)   
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35S radioactive sulfur 35 
A Adenine 
AA  Amino Acid 
ABC Ammonium bicarbonate 
Akt2 V-akt murine thymoma viral oncogene homolog 2 
alanine  Ala, A 
AP-2  Transcription factor AP-2 
AP-3 Transcription factor AP-3 
arginine  Arg, R 
asparagine  Asn, N 
aspartic acid  Asp, D 
ATPase  Enzyme that cleaves ATP 
BCL6 B-cell lymphoma 6 protein 
BLAST Basic Local Alignment SearchTool 
BRAC2 breast cancer type 2 susceptibility protein 
BRCA1 breast cancer type 1 susceptibility protein 
BRMS1 Breast cancer metastasis suppressor 1 
BTB/POZ broad-complex tramtrack, bric a brac, poxvirus zinc finger 
BTBk BTB (POZ) domain contain Kelch repeat 
BTB-ZF BTB (POZ) -Zinc finger 
C Cytosine 
C12orf51 Chromosome 12 open reading frame 51 
Cdc32 Cell division control protein 42 homolog 
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cdc37  Cell division cycle 37 homolog 
cdk5 Cyclin-dependent kinase 5 
CKI Casein kinase 1 
CKII Casein kinase 2 
CRL Cullin-RING E3 ligase  
C-terminal carboxylic acid terminal  
Cul  cullin 
CXCL14 Chemokine (C-X-C motif) ligand 14 
cysteine  Cys, C 
DBC2 Deleted in Breast Cancer 2  
DCP2 mRNA-decapping enzyme 2 
DMEM Dulbecco/Vogt modified Eagle's minimal essential medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
E.coli Escherichia coli 
E1 ubiquitin-activating enzyme 
E2  ubiquitin-conjugating enzyme  
E3 ubiquitin-protein ligase 
EDTA Ethylenediaminetetraacetic acid 
EF2 E2F transcription factor family 
ER endoplasmic reticulum 
FHA Forkhead-associated domain 
G Guanine 
G cycle  GTPase cycel 
G proteins  GTPase proteins 
G3BP1 Ras GTPase-activating protein-binding protein 1 
GA geldanamycin 
GAP GTPase activating proteins 
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GDF GDI disassoication factor 
GDI Guanine disassoication inhibitor 
GDP guanosine diphosphate  
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
glutamic acid  Glu, E 
glutamine  Gln, Q 
glycine  Gly, G 
GMP guanosine monophosphate  
GMP Guanosine monophosphate 
GSK3 Glycogen synthase kinase 3 
GTP guanosine triphosphate 
GTP Guanosine-5'-triphosphate 
GTPase guanosine triphosphatase  
GTPase Enzyme that cleaves GTP 
HECT Homologous to the E6-AP Carboxyl Terminus domain 
HeLa "Henrietta Lacks" cervical caner- epithelial 
histidine  His, H 
Hop  Stress-induced-phosphoprotein 1 
Hsc70 Heat shock 70 kDa protein 8 
Hsp70 70 kilodalton heat shock proteins 
Hsp90  Heat Shock protein 90kDa 
IgG  Immunoglobulin G 
isoleucine  Ile, I 
K562 Lymphoblastoid 
kDa kiloDalton 
KOAc Potassium acetate  
LC-MS Liquid chromatography–mass spectrometry 
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LC-MS-MS Liquid chromatography–mass spectrometry-mass spectrometry 
Lck Lymphocyte-specific protein tyrosine kinase 
leucine  Leu, L 
LOH Loss of heterozygosity  
lysine  Lys, K 
MALDI-TOF  Matrix-assisted laser desorption/ionization-time of flight 
MATH Meprin and TRAF homology domain 
MCF-7 "Michigan Cancer Foundation-7" Invasive breast ductal carcinoma 
methionine  Met, M 
Mg(Oac)2 magnesium acetate 
MG132 Z-Leu-Leu-Leu-al 
Miz-1 Zinc finger and BTB domain containing 17 
MoO4 molybdate 
MS mass spectrometry 
N2 Nitrogen 
NaCl sodium chloride  
NCBI National Center for Biotechnology Information 
Nedd8 Neural precursor cell expressed, developmentally down-regulated 8 
NLS  Nuclear localization signal 
NOT4 CCR4-NOT transcription complex subunit 4 
N-terminal amino terminal  
p23 Prostaglandin E synthase 3 
p38MAPK P38 mitogen-activated protein kinase 
Pak1 P21 protein (Cdc42/Rac)-activated kinase 1 
PCD Programmed Cell Death 
PCR Polymerase chain reaction 
pfu DNA polymerase from the archaeon Pyrococcus furiosus 
phenylalanine  Phe, F 
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PHYRE Protein Homology/AnalogY Recognition Engine 
PKC Protein Kinase C 
PLZF Promyelocytic leukemia zinc-finger 
Poly-A Polyadenylation 
ProD-kinase  Proline directed kinase 1 
proline  Pro, P 
psi pounds per square inch 
PSI-BLAST Position-Specific Iterative BLAST 
PVDF Polyvinylidene fluoride 
PyMOL Molecular modeling software 
Rap1 Ras-related protein 1 
Rap1Gap Rap1 GTPase-activating protein 1 
Ras Rat sarcoma 
Rbx1 RING-Box protein 1 
RDA Representational Difference Analysis 
Rho Ras homology  
RhoH Ras homolog gene family, member H 
RhoU Ras homolog gene family, member U 
RING Really interesting new gene 
Rnd1 Rho family GTPase 1 
Rnd3 Rho family GTPase 1 
rpm rotations per minute  
RRL Rabbit reticulocyte lysate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gelelectrophoresis 
serine  Ser, S 
Skp1 S-phase kinase-associated protein 1 
SOCS suppressor of cytokine signaling 




T-47D Breast ductal carcinoma 
T7  T7 RNA polymerase from the T7 bacteriophage  
TBC tre-2/USP6, BUB2, cdc16 domain  
threonine  Thr, T 
TIA-1 Nucleolysin TIA-1 isoform p40 
TnT Coupled trasncription translation 
tryptophan  Trp, W 
tyrosine  Tyr, Y 
UBE Ubiquitin binding entity  
UPS Ubiquitin/26S proteasome pathway  
UTR untranslated region  
valine  Val, V 
VSVG Vesicular stomatitis virus glycoprotein 
WASP Wiskott–Aldrich Syndrome Protein 













PCR primers  
 
Primer Name  Primer Sequence 
CACC Flag Link 5' - CACCATGGACTACAAGGACGACGATGACAAGAACACCGGCGCGGCG - 3' 
CACC Link DBC2 5' - CACCGGCGCGGCATGGATTCTGACATGGATTATGAAAGG - 3' 
DBC2 NΔ207 CACC 5' - CACCGGCGCGGCGATGCTCATCTCCCGCCGCCACCT - 3' 
DBC2 NΔ258CACC 5' - CACCGGCGCGGCGATGCACCTCCTGGAGGACCCGCTC - 3' 
DBC2 NΔ297CACC 5' - CACCGGCGCGGCGATGCTCATGGACCTGAGTGAGGGGGA - 3' 
DBC2 NΔ319CACC 5' - CACCGGCGCGGCGATGCACCAGGGCCACTCTGATCAA - 3' 
DBC2 NΔ335CACC 5' - CACCGGCGCGGCGATGGGGCGAGACTTCCTGCTCCGA - 3' 
DBC2 NΔ421CACC 5' - CACCGGCGCGGCGATGCAGCCGGGGCCCTTCCGGGCT - 3' 
DBC2 NΔ470CACC 5' - CACCGGCGCGGCGATGGAGGCCTTCATGAACCAGGAGATC - 3' 
DBC2 NΔ501CACC 5' - CACCGGCGCGGCGATGGTGACCTTCATCCTGGATGAT - 3' 
DBC2 NΔ593CACC 5' - CACCGGCGCGGCGATGACAGTGACCGGGCTGATGGAAGC - 3' 
DBC2 NΔ675CACC 5' - CACCGGCGCGGCGATGGATCATTACCAGCGGGCAC - 3' 
DBC2 Nt Back 5' - TCAGACCACAGCCGAGGAGGAAGATGGGGATGA - 3' 
DBC2_QC C559Y for 5' - GCCGTGCTGGAATACCTCTACACCGGCATGTTCACCTCC - 3' 
DBC2_QC C559Y back 5' - GGAGGTGAACATGCCGGTGTAGAGGTATTCCAGCACGGC - 3' 
DBC2_QC G99R for 5' - GCTTTGCTTATGGGAGATCTGATGTGGTGG - 3' 
DBC2_QC G99R back 5' - CCACCACATCAGATCTCCCATAAGCAAAGC - 3' 
D2 CΔ210 UAG top 5' - CGAGCTGCACTCATCTCCTAGCGCCACCTGCAGTTCTGG - 3' 
D2 CΔ210 UAG bottom 5' - CCAGAACTGCAGGTGGCGCTAGGAGATGAGTGCAGVTCG - 3' 
pcDNA3.1 HisΔ top 5' - GGTCTCGATTCTACGTGAACCGGTCATCATCACCAT - 3' 
pcDNA3.1 HisΔ bottom 5' - ATGGAGATGATGACCGGTTCACGTAGAATCGAGACC - 3' 
top DBC2 QC266(2) stop 5' - CTGGAGGACCCGCTCTGCTAGGACGTCATCCTGGTGCTG - 3' 
bottom DBC2 QC266(2) 
stop 5' - CAGCACCAGGATGACGTCCTAGCAGCGCGGGTCCTCCTG - 3' 
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I191V top 5' - CCCTACTATGAGACCAGCGTGAGGGCCCAGTTCGGCATCAAGGACGTC - 3' 
I191V bottom 5' - GACGTCCTTGATGCCGAACTGGGCCCTCACGCTGGTCTCATAGTAGGG - 3' 
Rho_V191I Top 2 5' - CCCTACTATGAGACCAGCGTGATAGCCCAGTTCGGCATCAAGGAC - 3' 
Rho_V191I bottom 2 5' - GTCCTTGATGCCGAACTGGGCTATCACGCTGGTCTCATAGTAGGG - 3' 
Rho_V191I Top.3 5' - CATCCCCTACTATGAGACCAGCGTG ATCGCCCAGTTCGGCATCAAGGACGTC - 3' 
Rho_V191I bottom.3 5' - GACGTCCTTGATGCCGAACTGGGCGATCACGCTGGTCTCATAGTAGGGGATG - 3' 
I191M top 5' - CCCTACTATGAGACCAGCGTGATGGCCCAGTTCGGCATCAAGGACGTC - 3' 
I191M bottom 5' - GACGTCCTTGATGCCGAACTGGGCCATCACGCTGGTCTCATAGTAGGG - 3' 
I191K top 5' - CCCTACTATGAGACCAGCGTGAAGGCCCAGTTCGGCATCAAGGACGTC - 3' 
I191K bottom 5' - GACGTCCTTGATGCCGAACTGGGCCTTCACGCTGGTCTCATAGTAGGG - 3' 
Q141K  top 5' - GACCCTGTCATCTTGGTGGGCTGAAGTTGGACCTGCGCTACGCTGACCTGGAGGCTGTC - 3' 
Q141K bottom 5' - GACAGCCTCCAGGTCAGCGTAGCGCAGGTCCAACTTGCAGCCCACCAAGATGACAGGGTC - 3' 
Q141R top 5' - GCACCTGTCATCTTGGTGGGCTGCCGGTTGGACCTGCGCTACGCTGACCTGGAGGCTGTC - 3' 
Q141R bottom 5' - GACAGCCTCCAGGTCAGCGTAGCGCAGGTCCAACCTGCAGCCCACCAAGATGACAGGGTC - 3' 
S189K top 5' - GGGCATCCCCTACTATGAGACCAAGGTGGTGGCCCAGTTCGGCATCAAGGACGTC - 3' 
S189K bottom 5' - GACGTCCTTGATGCCGAACTGGGCCACCACctTGGTCTCATAGTAGGGGATGCCC - 3' 
S189R top 5' - GGGCATCCCCTACTATGAGACCAGGGTGGTGGCCCAGTTCGGCATCAAGGACGTC - 3' 
S189R bottom 5' -GACGTCCTTGATGCCGAACTGGGCCACCACCCTGGTCTCATAGTAGGGGATGCCC  - 3' 
f-DBC2 T7 PCR forward 5' - GAGAGAGATAATACGACTCACTATAGGAGACGCCACCATGGACTACAAGGACGACGATGACAAG - 3' 
f-DBC2 T7 PCR reverse 5' - TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCAGACCACAGCCGAGGAGGAAGATGGGGATG - 3' 
DBC2 Rho forward 5' - CACCATGGATTCTGACATGGATTATGAA - 3' 
DBC2 Rho reverse 5' - GGAGATGAGTGCAGCTCGG - 3' 
D2 S251A top 5' - CCCTCCTCGCTGGCGGAGGGAGGGTC - 3' 
D2 S251A bottom 5' - GACCCTCCCTCCGCCAGCGAGGAGGG - 3' 
D2 S250A top 5' - CGACCCTCCCGCCAGCAGCGAGGAG - 3' 
D2 S250A bottom 5' - CTCCTCGCTGCTGGCGGGAGGGTCG - 3' 
D2 K673R top 5' - CCTGTGTGGTACCTGAGGGAGGAAGATCATTACCAG - 3' 
D2 K673R bottom 5' - CTGGTAATGATCTTCTCTCCTCAGGTACCACACAGG - 3' 
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D2 K673R top2 5' - GGCCACCTGTGTGGTACCTGAGGGAGGAAGATCATTACCAGCGGGC - 3' 
D2 K673R bottom2 5' - GCCCGCTGGTAATGATCTTCCTCCCTCAGGTACCACACAGGGGTCC - 3' 
D2 K673R top3 5' - CGGTGGCCACCTGTGTGGTACCTGCGCGAGGAAGATCATTACCAGCGGGCACGG - 3' 
D2 K673R bottom3 5' - CCGTGCCCGCTGGTAATGATCTTCCTCGCGCAGGTACCACACAGGGGTCCACCG - 3' 
D2 CΔ470 top 5' - GTGGCCAACATTCTCAACAATTAGGCCTTCATGAACCAG - 3' 
D2 CΔ470 bottom 5' - CTCCTGGTTCATGAAGGCCTAATTGTTGAGATTGTTGGC - 3' 
D2 CΔ470 top 2 5' - GATGGTGGCCAACATTCTCAACAATTAGGCCTTCATGAACCAGGAG  - 3' 
D2 CΔ470 bottom 2 5' - CTCCTGGTTCATGAAGGCCTAATTGTTGAGAATGTTGGCCACCATC - 3' 
D2 CΔ600 top 5' - GTGACCGGGCTGATGTGAGCGACCCAGATGATGGTG - 3' 
D2 CΔ600 bottom 5' - CACCATCATCTGGGTCGCTCACATCAGCCCGGTCAC - 3' 
D2 CΔ600 top 2 5' - CACAGTGACCGGGCTGATGTGAGCGACCCAGATGATGGTGGAC - 3' 
D2 CΔ600 bottom 2 5' - GTCCACCATCATCTGGGTCGCTCACATCAGCCCGGTCACTGTG - 3' 
D2 CΔ210 top 5' - GCTGCACTCATCTCCTGACGCCACCTGCAG - 3' 
D2 CΔ210 bottom 5' - CTGCAGGTGGCGTCAGGAGATGAGTGCAGC - 3' 
HindIII-Flag_link 5' - CTAGTTAAGCTTGGATGGACTACAAGGACGACGATGACAGG - 3' 
XbaI-D2-I191V-back  5' - CCCTCTAGACTCGTCAGACCACAGCCGAGGAGGAAGATG - 3' 
For.DBC2 QΔ266.STOP 5' - CTGGAGGACCCGCTCTGCTAGGACGTCATCCTGGTGCTG - 3' 
Rev.DBC2 QΔ266.STOP 5' - GACCTCCTGGGCGAGACGATCCTGCAGTACGACCACGAC - 3' 
DBC2 NΔ210.cacc 5' - CACCGGCGCGGCGATGATCCCGCCGCCACCTGCAGTTCT - 3' 
DBC2 CΔ 469 top 5' - GGCCAACATTCTCAACTAATGAGGCCTTCATGAACCAGG - 3' 
DBC2 Cdelta 469 bottom 5' - CCGGTTGTAAGAGTTGATTACTCCGGAAGTACTTGGTCC - 3' 
DBC2 NΔ210.cacc 5' - CACCGGCGCGGCGATGATCCCGCCGCCACCTGCAGTTCT - 3' 
DBC2 NΔ500.cacc 5' - CACCGGCGCGGCGATGTCAGATGTGACCTTCATCCTGGATG - 3' 
D2 CΔ 210 uaa Top 5' - CGAGCTGCACTCATCTCCTAGCGCCACCTGCAGTTCTGG - 3' 
D2 CΔ 210 uaa Bottom 5' - CCAGAACTGCAGGTGGCGCTAGGAGATGAGTGCAGCTCG - 3' 
D2 L300V top 5' - GACCTGTTCCTCATGGACGTGAGTGAGGGGGAG - 3' 
D2 L300V bottom 5' - CTCCCCCTCACTCACGTCCATGAGGACCAGGTC - 3' 
DBC2 Ring forward 5' - CACCATGGTGGACATCGATGGGGACGTC - 3' 
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DBC2 Ring reverse  5' - CCGTGCCCGCTGGTAATGATCTTC - 3' 
DBC2 CACC topo 151 5' - CACCATGGATTCTGACATGGATTATGAAAGG - 3' 
DBC2 back topo 151 5' - TCAGACCACAGCCGAGGAGGAAGATG - 3' 
pSP64T f-DBC2 HindIII 
for  5' - GACAAGCTTATGGACTACAAGGACGACGATGACAAGAACACC - 3'
pSP64T f-DBC2 BamHI 
back 5' - GCGGGATCCTCAGACCACAGCCGAGGAGGAAGATG - 3' 
DBC2 TA TOPO for 5' - ATGGATTCTGACATGGATTATGAAAGG - 3' 
DBC2 no stop back 
topo/TA 5' - CCAGACCACAGCCGAGGAGGAAGATG - 3' 
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